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10  Chapter 1
Organ transplants, immune suppression and 
complications
One of the most remarkable feats of modern Western medicine in the last century has 
undoubtedly been organ transplantations. The most serious complication which had to be 
overcome was the rejection of the allograft by the host immune system. As the mortality 
from immunologic and non-immunologic graft failure diminished and life expectancy 
of organ transplant recipients increased, other complications such as infections and 
malignancies rose in frequency. Life-threatening infections were reduced by a more prudent 
use of immunosuppressive drugs, combined with improved therapies against infections. 
Inclusion of steroids in the medication of organ transplant recipients have contributed to 
the occurrence of cardiovascular diseases, but this is ameliorated by aggressive treatment 
of hypertension and by steroid-free immunosuppressive regimens. A major complication, 
which worsens with prolonged graft survival, is the increase in malignancies, among which 
skin carcinomas are most dominant in white-skinned renal transplant recipients1, 2 (fi gure 
1). The carcinomas cause substantial mortality among organ transplant recipients3, and the 
abundance of precursor lesions (actinic keratoses) can have a serious blemishing effect.
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Hoxtell et al, 1977   36 (10-93)
Kinlen et al, 1979 23 (4-68)
Gupta et al, 1986 18 (17-20)
Hartevelt et al, 1990 253 (172-334)
Gjesvik et al, 2000 49 (33-70)
Moloney et al, 2006 82 (73-91)
Other organs +/- kidney transplantations
Adami et al, 2003 56 (50-63)
Jensen et al, 1999 65 (53-79)
Lindelof et al, 2000 93 (73-116)
Lindelof et al, 2000 109 (95-123)
Gjersvik et al, 2000 177 (81-336)
Haagsma et al, 2001 70 (28-144)
Squamous cell carcinoma SIR (95%CI)
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Figure 1: (A) Photo of an SCC on the face (B) Table showing the increased SCC risk in organ 
transplant recipients (adapted with permission57). 
Skin carcinomas and ultraviolet (UV) radiation
Skin carcinomas are the most common form of cancer among Caucasians and are steadily 
increasing: in the USA over 1.3 million cases per year4 and in the Netherlands over 35.000 
cases a year5. The skin carcinomas in the general populations are clearly related to solar 
UV exposure6 and so are the skin carcinomas in organ transplantation recipients2, 7, 8, as 
refl ected by predominant occurrence in sun-exposed skin. A striking observation is that the 
ratio of squamous cell carcinoma over basal cell carcinoma in the general population is 
around 1:3, whereas the immunosuppressed population develops these neoplasms in the 
inverse ratio of 4:19. In Europe and the USA 40-61%10, 11 of the organ transplant recipients 
developed skin cancer after 20 years, a fi gure that is even higher in Australia, where the 20 
years prevalence reaches 70-82%12, 13. From classic animal experiments it is known that 
UV-induced skin cancers are antigenic and subject to elimination by the immune system, 
but a sub-carcinogenic course of UV irradiations can suppress the rejection and even 
induce specifi c tolerance toward the tumor14. Susceptibility to UV-induced suppression 
of cellular immunity (contact hypersensitivity) was found to be positively correlated with 
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skin carcinoma in humans15. Hence, the dramatic increase of skin carcinomas in immune 
suppressed allograft recipients was immediately and automatically attributed to the lack of 
adequate cellular immunity directed against the skin carcinomas. Experiments by Kelly et 
al.16 confi rmed that the immunosuppressants azathioprine and cyclosporin A speeded up 
UV carcinogenesis in a hairless mouse model.
Modes of action of immunosuppressants
Immunosuppressants work through different mechanisms (fi gure 2).
Blockage of purine synthesis: Azathioprine (Aza) and mycophenolate mofetil (MMF), or 
rather their respective metabolites 6-mercaptopurine (6MP) and mycophenolic acid (MPA), 
interfere with the synthesis of purines17. The older drug, Aza/6MP, does it rather crudely by 
competing in the pathway of purine synthesis: as a substrate of thiopurine S-methyltransferase, 
it leads inhibition of de novo purine synthesis or, as a substrate of inosine monophosphate 
dehydrogenase and guanosine monophosphate synthetase, it competes for incorporation 
into the DNA and RNA as a 6-thioguanine pseudo-base18, 19. MMF/MPA specifi cally inhibits 
inosine monophosphate dehydrogenase, and does not lead to incorporation of pseudo-
bases in the DNA20. T lymphocytes are thought to be particularly vulnerable because they 
have no salvage pathway for purine synthesis that goes astray. With blocked purine synthesis 
the T cells are unable to proliferate.
Calcineurin inhibition: Calcineurin is a calcium-inducible phosphatase that serves to expose 
a part of the nuclear factor of activated T cells (NFAT), thereby causing this transcription 
factor to translocate to the nucleus; as the name of the factor suggests, this translocation is an 
essential step in activation of T cells (e.g. in IL2 production after TCR/CD3 activation)17, 21. 
Cyclosporin A (CsA) combines with cyclophilin to inhibit calcineurin, and tacrolimus (Tac, 
also known as FK506) does the same by combining with FKBP (FK506 binding protein or 
immunophilin)22.
Blockage of downstream part of the Akt pathway/mTOR: The mammalian Target of Rapamycin 
(mTOR, or FKBP 12-rapamycin-associated protein, FRAP) activates p70S6 kinase and 
indirectly eIF-4E to induce protein synthesis and translation, respectively. The latter is 
mediated through elimination of p27KIP which also facilitates the G1 to S phase transition. 
Rapamycin (Rapa, also known as sirolimus) is a structural analogue of Tac and also binds 
to FKBP23. This complex does, however, not target calcineurin, but binds and blocks mTOR 
specifi cally in the protein complex mTORC1. Thus, Rapa can obstruct proliferative signaling 
through the IL2 receptor.
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Although these immunosuppressants are used with the aim to inhibit the immune system, it 


















Figure 2: Graphical representation of immunosuppressants, their binding partners, their modes of 
action, as well as known effects on DNA repair, apoptosis and photogenotoxicity.
Secondary effects of immunosuppressants
DNA repair and apoptosis: In parallel to experiments on the effects of Aza and CsA on UV 
carcinogenesis in hairless mice, Kelly et al found these immunosuppressants to lower 
DNA repair as measured by unscheduled DNA synthesis (UDS) in the epidermis of the 
mice after UV exposure24. CsA was also found to reduce UV-induced apoptosis (sunburn 
cells) in the skin of BALB/c mice25. Herman et al.26 showed that CsA, but not Aza, lowered 
repair of UV-induced DNA damage in peripheral blood mononuclear cells. More recently, 
the group of Yarosh showed that the calcineurin inhibitors CsA and ascomycin impaired 
the repair of UV-induced cyclobutane pyrimidine dimers (CPDs) in the genomic DNA of 
human keratinocytes, and that the apoptotic reaction of these cells was also lowered27. These 
down-regulated responses can enhance mutagenesis and malignant transformation. The 
authors emphasize that their data may have serious implications for the topical calcineurin 
inhibitors on sun-exposed skin (in contrast, the European Dermatology Forum concluded 
that available data indicated that topical calcineurin inhibitors, e.g. for eczema patients, are 
safe28). Interestingly, Yarosh et al. found that NFAT was translocated to the nuclei of the 
keratinocytes after short-wavelength UV-B exposure, and that CsA and ascomycin inhibited 
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this translocation27. A similar result of NFAT activity was reported by others for fi broblasts 
following exposure to low doses of long-wavelength UV-A radiation29. Inhibition of this 
activity by CsA or Tac increased the cytotoxicity of UV-A exposures.
DNA damage: Besides the effect of Aza on DNA repair, Kelly et al already drew attention in 
the late 80s to the potential photosensitizing effect of Aza on the DNA: the 6-thioguanine 
pseudo-base absorbs UV-A radiation30. More recently, Karran’s group found that the UV-A 
photo-oxidation product, guanine sulfonate, in the DNA is an obstructive lesion that 
blocks replication and most likely also transcription31. In concordance with a blockage 
of transcription32, Karran’s group found that organ recipients on Aza show an increased 
erythemal sensitivity to UV-A radiation. The stalling of the DNA replication fork is overcome 
by switching to error-prone polymerases in a process dubbed ‘lesional bypass’, which 
increases the likelihood of mutations. The authors infer that the ensuing photosensitized 
mutagenesis could (in part) explain the increase in skin carcinomas among organ transplant 
patients in old cohorts on Aza. If the guanine sulphonate is an important mutagenic lesion, 
one would expect this to be refl ected in mutation spectra such as that of the P53 tumor 
suppressor gene in skin carcinomas. In the general population, the P53 gene is mutated 
in 50-90% of skin carcinomas. These mutations are typical of UVB radiation (associated 
with di-pyrimidine sites targets for UV-B induced pyrimidine dimers, and mostly C to T 
transitions, sometimes even CC to TT tandem mutations)33, 34. However, the P53 mutation 
spectrum in skin carcinomas from an early cohort of renal transplant recipients showed no 
obvious deviations35, and therefore no discernable effect of guanine sulphonate. But this 
sample with 12 mutations from 23 carcinomas was rather small, and did not include any 
CC to TT tandem transitions.
Stress response signaling: Besides apoptotic signals, UV irradiation also triggers survival 
signaling of keratinocytes through EGF-R/PI3-K/AKT/S6K36 and leads to activation of mTOR 
and p70S6 kinase through PI3-K, surprisingly not through Akt137. Upon UV exposure mTOR 
mediates phosphorylation and activation of P53 and BRCA138. And in keratinocytes mTOR 
relays the UV-induced signaling for TNF-alpha (and IL 10 in murine keratinocytes), involved 
in UV-induced immunosuppression39. Rapa blocks these UV-induced actions of mTOR, 
and the net outcome is not directly clear. Interestingly, inhibition of survival/anti-apoptotic 
signaling by Rapa results in apoptosis in p53-null cells, but not in cells with functional p53 
which are in G1 phase40.
Angiogenesis: MMF was developed as an anti-neoplastic agent and was proven to inhibit 
tumor cell proliferation41, to modulate adhesion molecules resulting in impaired 
invasiveness42 and to induce terminal differentiation43. CsA and Rapa were shown to have 
widely different effects on angiogenesis: while both offered adequate immunosuppression 
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to maintain a heart transplant in mice, CsA stimulated angiogenesis and outgrowth of 
inoculated tumor cells, whereas Rapa impaired these processes44. A decrease in the release 
of vascular endothelial growth factor (VEGF) from tumor cells and decreased responsiveness 
of endothelial cells appears to underlie the anti-angiogenic and anti-tumor growth effects of 
Rapa45, whereas CsA stimulates VEGF production46.
Reduction of skin carcinoma burden in organ transplant patients
As mentioned earlier, the increase in skin carcinomas among organ transplant recipients was 
considered a logic and inevitable consequence of immunosuppression. But the introduction 
of novel immunosuppressants with anti-tumor effects altered our thinking. At the outset of 
the present study in 2006, a clinical trial was already started in which after transplantation 
of a kidney the recipients were initially kept on a three-months regimen of Rapa-CsA and 
steroids. After this initial regimen CsA was withdrawn and Rapa increased for half of the 
group while the other half continued on the original regimen. The former half showed a 
dramatic 3 fold lower rate of occurrences of skin carcinomas after 5 years47. Evidently, there 
is ample room for improvement in minimizing the skin carcinoma risk, but the possibilities 
of experimentation with actual organ transplant recipients are, of course, very limited. A 
systematic approach in appropriate experimental models of UV carcinogenesis is, therefore, 
called for. To this end, two experimental models are used in this thesis, which are described 
in the next paragraphs.
The human skin equivalent
Human skin equivalents (HSEs) are three-dimensional tissue cultures containing a dermal 
matrix seeded with primary fi broblasts and an overlying epidermis consisting of primary 
keratinocytes. The epidermis is formed spontaneously by keratinocytes seeded on the 
dermal matrix under specifi c culturing conditions. Supplementation of culture media with 
serum or exogenous growth factors is mostly not required when fi broblasts are included 
into the dermal compartment48, resulting in a local environment that is similar to that 
of in vivo tissue. HSEs that are formed under these conditions resemble native human 
skin in structure (fi gure 3A and B) and expression of basal membrane, proliferation and 
differentiation markers48. Thus, HSEs appear to be suitable models for investigating cellular 
responses to UV exposure of epidermal keratinocytes in the skin. Due to their limited life-
span (maximally around two months), HSEs are not suitable for studying long-term effects 
of repeated UV exposures.
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Figure 3: Hematoxylin and eosin stained cross sections of (A) native human skin, (B) human skin 
equivalent, (C) hairless mouse skin (adapted with permission58). Scale bars: 50 μm.
The hairless mouse model
UV radiation is an important factor in the induction of skin cancer in humans. For ethical 
reasons, UV-carcinogenesis cannot be studied experimentally in humans; therefore 
epidemiological data are used for risk assessments. These data can be confounded by many 
factors that cannot be corrected for. For instance, due to continuing development of new 
immunosuppressive agents patients are differently treated over time, making it impossible 
to compare older and newer immunosuppressants on skin cancer risk. Experimental 
studies on UV carcinogenesis are therefore necessary to gain insight in mechanistic effects 
of immunosuppressants on UV-induced skin cancer development. The immunocompetent 
hairless mouse strain (SKH1) is one of the mouse models extensively used for studying UV 
carcinogenesis. Skin of hairless mice morphologically resembles human skin; both consist 
of a dermis and an epidermis, where the epidermis consists of a basal, a spinous, a granular, 
and a cornifi ed layer (fi gure 3). There are however several notable differences between skin of 
hairless mice and human skin. Human epidermis consists of 5-8 viable cell layers, whereas 
mouse epidermis comprises only 1-2 cell layers. Unlike human skin, hairless mouse skin 
contains degenerated hair follicles and no sweat glands or dermal papillae. 
When hairless mice are repeatedly UV-irradiated clusters of keratinocytes expressing 
mutant p53 (mut-p53 cell clusters) develop in the epidermis. In previous studies numbers 
of mut-p53 cell clusters were correlated with the rate of tumor development after chronic 
UV irradiations49, 50. Mut-p53 cell clusters develop as a clonal expansion of a mutated 
keratinocyte and occur prior to skin tumors. Skin tumors that are induced in hairless mice are 
predominantly squamous cell carcinomas (SCCs) and precursor lesions (actinic keratoses). 
Since most SCCs harbor mutations in the p53 gene similar to those in mut-p53 cell 
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clusters51, 52, p53 mutations are considered to be early events in SCC formation and mut-p53 
cell clusters precursors of SCCs. As stated earlier, SCCs are the type of non-melanoma skin 
tumor for which the risk is the most increased in transplant patients10, 53. In conclusion, 
the hairless mouse model appears to be the most suitable animal model available to study 
effects of immunosuppressants on UV-induced skin cancer. 
Aim and outline of the thesis
Increased skin cancer risk is a serious problem for organ transplant recipients. Immuno-
suppressive therapy is considered an important risk factor for skin cancer development. 
The aim of the present study was to provide experimental data which could contribute to 
minimize the (skin) carcinogenic risk from immunosuppressive drugs. The main incentive 
for the study was the recognition that the impact of different immunosuppressants on (UV 
responses of) skin cells could differ widely, with potentially corresponding differential 
impacts on UV carcinogenesis. More specifi cally, it was assessed whether the reported anti- 
and pro-apoptotic effects of CsA and Rapa, respectively, corresponded directly with possibly 
different impacts of these drugs on UV-induced mut-p53 cell clusters and skin carcinogenesis. 
In this respect, it is interesting to note that the mut-p53 cell clusters were proven to be 
non-immunogenic (in contrast to skin carcinomas)54. Their occurrence can therefore be 
considered to be the result of pure local (UV and drug) effects in the skin, independent of 
any systemic immunosuppressive effect. Consequently, the experiments presented in this 
thesis focus on modulating effects of immunosuppressants on the responses of skin cells 
to UV irradiation, and the UV induction of skin carcinomas and precursor lesions. With 
reported adverse effects on skin cells and pro-tumor effects of classic immunosuppressants 
and anti-tumor effects of novel immunosuppressants, Rapa and MMF, the study fi rst focused 
on the impacts of these novel drugs on the formation of primary skin carcinomas by UV 
exposures. Subsequently, the study was expanded to include other effects (e.g. on mutation 
and expression of p53, proliferation and apoptosis) and the main immunosuppressants 
currently used in organ transplant recipients.
Angiogenesis and outgrowth of tumor implants have previously been shown to be inhibited 
by the immunosuppressants MMF and Rapa41, 45, 55. Also, Rapa could increase apoptotic 
responses in p53 dysfunctional cells40. Hence, these drugs are very interesting as they 
could lower the skin cancer risk by these local effects in the skin. Chapter 2 describes the 
effects of MMF and Rapa on UV carcinogenesis in hairless mice, more specifi cally on tumor 
development, p53 mutational spectra and expression of vascular endothelial growth factor 
(Vegf-a).
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Results of chapter 2 showed that skin tumors (>2mm) of Rapa-treated mice harbor an 
altered p53 mutational spectrum. In order to assess at which stage in tumor development 
this altered mutational spectrum develops, mutational spectra of small skin tumors (<2mm) 
and mut-p53 cell clusters are determined in chapter 3. During the analysis, Rapa was found 
to decrease numbers of mut-p53 cell clusters. Apparently and surprisingly, this had no effect 
on the onset of tumors (chapter 2). It was therefore investigated whether Rapa inhibits 
formation of these cell clusters, or whether Rapa induces apoptosis specifi cally in these cell 
clusters or decreases p53 protein expression. 
Working mechanisms and effects in the skin differ between immunosuppressants. 
Experiments reported on in chapter 4 compare the effects of immunosuppressants on the 
sequence of events leading up to tumor formation, to assess whether early effects on apoptosis 
and frequency of p53 mutations are predictive of the risk of skin cancer development. The 
main immunosuppressants (CsA, Tac, Aza, MMF and Rapa) are compared in a human skin 
model for short term effects of skin cells after UV irradiation and in a hairless mouse model 
for UV carcinogenesis.
In a pioneering study, the immunosuppressive drug CsA increased UV-carcinogenesis16, 
whereas other studies showed that CsA decreased UV-induced tumor development56 (chapter 
4). These confl icting results may be explained by the use of different treatment schemes, i.e. 
UV exposure and CsA treatment. Chapter 5 compares the net effect on UV carcinogenesis of 
three experimental protocols with two ways of administering CsA. 
In chapter 6 all results are summarized and discussed. 
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Abstract 
Increased skin cancer risk in organ transplant recipients has been experimentally emulated 
with enhanced UV carcinogenesis from administering conventional immunosuppressants. 
However, a newer generation immunosuppressive drugs, rapamycin (Rapa) and 
mycophenolate mofetil (MMF), have been shown to impair angiogenesis and outgrowth 
of tumor implants. To ascertain the overall effect on UV carcinogenesis, Rapa and MMF 
were admixed into the food-pellets of hairless SKH1 mice receiving daily sub-sunburn 
UV dosages. With immunosuppressive blood levels neither of the drugs affected onset 
of tumors (<2mm), but in contrast to MMF, Rapa signifi cantly increased latency of large 
tumors (4mm, medians of 190 vs 125 days) and reduced their multiplicity (1.6 vs 4.5 
tumors per mouse at 200 days). Interestingly, tumors (>2mm) from the Rapa-fed group 
showed a reduction in UV-signature p53 mutations (39% vs 90%) in favor of mutations 
from putative base oxidation. This shift in mutation spectrum was not essentially linked to 
the reduction in large tumors as it was absent in large tumors similarly reduced in number 
when feeding Rapa in combination with MMF, possibly owing to an antioxidant effect 
of MMF. Signifi cantly fewer tumor cells were Vegf-positive in the Rapa-fed groups, but a 
correspondingly reduced expression of Hif-1 target genes (Vegf, Ldha, Glut1, Pdk1) that 
would indicate altered glucose metabolism with increased oxidative stress was not found. 
Remarkably, we observed no effect of the immunosuppressants on UV-induced tumor onset, 
and with impaired tumor outgrowth Rapa could, therefore, strongly reduce skin carcinoma 
morbidity and mortality in organ transplant recipients.
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Introduction
One of the most remarkable feats of modern Western medicine in the last century has 
undoubtedly been organ transplantation. However, as the initially leading mortality from 
immunologic and non-immunologic graft failure diminished and life expectancy of organ 
transplant recipients increased, other complications have risen. A major complication, 
which worsens as the graft survival is extended, is posttransplant malignancy, among which 
skin carcinomas are most prominent1, 2. The carcinomas tend to be more aggressive in organ 
transplant recipients, causing substantial mortality3, and the abundance of precursor lesions 
(actinic keratoses) can have serious blemishing effects.
Skin carcinomas among white Caucasians are clearly related to solar UV exposure4, and 
so are the skin carcinomas in organ transplant recipients2, 5, as refl ected by predominant 
occurrence in sun-exposed skin. A striking observation is that the ratio of squamous cell 
carcinoma (SCC) over basal cell carcinoma (BCC) in the general population ranges around 
1:3, whereas the ratio is reversed in organ transplant recipients. In the Netherlands it was 
estimated that about 40% of the renal transplant recipients will have contracted at least one 
skin carcinoma by 20 years after transplantation6; in Australia this percentage is already 
exceeded after 9 years7.
From classic animal experiments it is known that UV-induced skin cancers are antigenic 
and subject to elimination by the immune system, but a sub-carcinogenic course of UV 
irradiations can suppress the rejection and even induce specifi c tolerance toward the tumor8. 
Hence, the dramatic increase of skin carcinomas in immune suppressed allograft recipients 
was immediately attributed to the lack of adequate cellular immunity directed against the skin 
carcinomas. Experiments by Australian groups9, 10 confi rmed that the immunosuppressants 
azathioprine and cyclosporine sped up UV carcinogenesis in a hairless mouse model. 
However, Kelly et al. also showed that these classical immunosuppressants adversely affected 
repair of UV-induced DNA damage in skin cells11. Moreover, this group recognized that 
azathioprine led to photosensitization of the DNA to long wavelength UV-A radiation, thus 
increasing the DNA damage caused by (solar) UV exposure12. This photosensitization has 
been confi rmed and studied in greater detail more recently13. Besides lowering DNA repair, 
cyclosporine was found to impair apoptotic responses to UV irradiation in BALB/c mice14, 
and these disruptive effects from calcineurin inhibitors, like cyclosporine, were confi rmed in 
human keratinocytes15. Aside from immunosuppression per se, these drug-specifi c adverse 
effects from classical immunosuppressants on skin cells are bound to increase the skin 
carcinoma risk related to (solar) UV exposure.
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A new generation of immunosuppressants may not have these drawbacks. In contrast to 
the traditional immunosuppressants, mycophenolate mofetil (MMF) and rapamycin 
(Rapa) impair the outgrowth of tumor inoculations16-19. Although MMF (or rather its 
metabolite mycophenolic acid), like azathioprine, interferes with purine synthesis, MMF 
does not give rise to incorporation of (6-thio-guanine) pseudo-bases that photosensitize 
DNA. Furthermore, Rapa operates through an entirely different mechanism, by blocking 
mTor (mammalian target of rapamycin) up-stream from 4Ebp1 and S6K in the Akt ‘survival 
pathway’20, thus regulating translation. The anti-angiogenic effect of Rapa is linked to both 
a reduction in production of Vegf-a in tumor cells and a diminished endothelial response17. 
Transcription of Vegf-a can be driven by Hif-1 which in turn is under translational control 
of mTor21-24. Furthermore, Rapa reportedly causes apoptosis in p53-null cells25 and impairs 
tumor outgrowth in p53-null mice26. As skin carcinomas raised by chronic UV exposure 
show an abundance of p53 mutations27 one might expect a Rapa-driven selective apoptotic 
response in these p53-mutant cells, which could lower the initiation rate of UV-induced skin 
carcinomas.
Considering these important differences between classical and novel immunosuppressants, 
a systematic approach to assess the skin carcinoma risk in appropriate models appears to be 
urgently needed. Here, we pose the question of how MMF and Rapa would affect the overall 
process of UV carcinogenesis. Both MMF and Rapa are expected to impair the outgrowth 
of UV-induced primary skin tumors, but Rapa may also lower the rate of initiation of these 
tumors. A net benefi cial effect would distinguish these novel suppressants from azathioprine 
and cyclosporine, which have been shown to enhance UV carcinogenesis in experiments 
with immunocompetent hairless mice10. Using the same hairless mouse model, we assessed 
the effect of Rapa and MMF treatment on UV carcinogenesis. 
Materials and Methods
The mice
SKH-1 hairless mice (Charles River, Maastricht, The Netherlands) entered the experiment at 
8 weeks of age; both male and female mice were used. The animal room was illuminated 
with yellow fl uorescent tubes (Philips TL40W/16, Eindhoven, The Netherlands) that did 
not emit any measurable UV radiation. The animals were housed individually in Macrolon 
type 1 cages (Techniplast, Bugguggiate, Italy) under a 12 h light-12 h dark cycle at 23°C, 
60% humidity. Standard chow was supplied in ample amounts (55-60 g/mouse/week), and 
drinking water was available ad libitum. Cage enrichment was absent to prevent shielding 
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of the animals from UV exposure. All experiments were performed in accordance with 
legislation and approval of the medical center’s ethics committee.
Groups on diets with admixtures of Rapa and MMF
To avoid repeated i.p. injections of the immunosuppressants, exploratory experiments 
with admixtures of the drugs to standard mouse chow were performed26. For the present 
experiment ssniff GmbH (Soest, Germany) supplied the food with Rapa at 20 mg/kg and 
MMF at 660 mg/kg. Four diet groups were formed: Rapa (n=10), MMF (n=10), Rapa and 
MMF (n=12) and a control group (n=10) fed the standard chow without admixtures. No 
apparent differences in food intake were observed between the four groups. With roughly 
50 g/wk of food intake by a 30 g mouse, we estimated a weekly intake of Rapa at about 
30 mg/kg and MMF at about 1 g/kg. All diets stocks were refrigerated to inhibit degradation. 
UV irradiation
The four groups were started on their respective diets 1 week before subjecting them to 
a regimen of daily UV exposure. TL-12/40W tubes (Philips, Eindhoven, The Netherlands; 
54% output in UVB – 280 to 315 nm – and 46% output in UVA – 315 to 400 nm) were used 
for daily UV exposure. The lamps were mounted over the cages with grid covers to allow 
undisturbed exposure of the mice. The lamps were automatically switched on daily from 
12.30 to 12.50 h. The threshold dose for a sunburn reaction (minimal edemal dose, MED) 
in the hairless SKH-1 mouse was ~500J/m2 UV under these lamps. The lamps were dimmed 
both electronically and by insertion of perforated metal sheets to expose the mice daily to 
250 J/m2 of UV radiation (0.5 MED).
Tumor assessment
The mice were inspected weekly for tumors which were registered for each mouse individually 
on maps (thus recording location, size, form and coloration/vascularisation). First smallest 
perceptible (<1mm in diameter) lesion had to be observed at least in two successive checkups 
to be confi rmed and counted. Upon removal of animals from the experiment, tumors were 
isolated from animals of each group for further analysis as described below. 
Histology and Immunohistochemistry
All stainings were performed on formalin-fi xed and paraffi n-embedded sections (5μm) of 
skin containing tumors. Hematoxylin and eosin (H&E) staining was performed for tumor 
staging. The following antibodies were used for immunohistochemistry: rat anti-mouse Vegf-a 
antibody (RELIATech, Braunschweig, Germany), rabbit anti-Hif-1 (Novus, Littleton/CO, 
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USA), rabbit anti-phospho-4Ebp1 (Thr 37/46, 236B4; Cell Signaling, Danvers/MA, USA), 
rabbit anti-phospho-S6 ribosomal protein (Ser235/236, 91B2; Cell Signaling, Danvers/MA, 
USA), rat anti-mouse CD34 (clone MEC 14.7; Acris Antibodies, Herford, Germany), using 
standard protocols and detection by diaminobenzidine. Staging and (immune-)histological 
evaluation of tumors from each group were performed by a blinded pathologist (Dr. A. 
Gaumann, University of Regensburg) who is experienced in mouse and human pathology, 
including diagnosis of actinic keratoses as proper precursors of squamous cell carcinomas28.
RNA and cDNA preparation
Excised samples of tumors, non-tumor dorsal skin, and ventral skin were treated with 
RNAlater-ICE (Ambion), snap-frozen in liquid nitrogen and stored in a freezer at -80°C. 
A biopsy of maximally 8 mm3 in volume was taken from every tumor by manual excision 
under a stereomicroscope. The biopsies were homogenized using a rotor stator homogenizer 
(Ultra-Turrax T8, IKA, Staufen, Germany), followed by RNA extraction with RNeasy mini kit 
(Qiagen, Valencia, Ca, USA). 0.5μg of total RNA was reverse-transcribed using the iScript 
cDNA Synthesis kit (Bio-Rad).
Mutational analysis
Tumor cDNA was used to amplify the entire coding sequences of the p53 transcript by RT-
PCR in two overlapping fragments (1st amplicon with primers CCTGGCTAAAGTTCTGTAGC 
forward and GCCTGTCTTCCAGATACTCG reverse, and 2nd amplicon with CCTGTCATCT-
TTTGTCCCTTC forward and GCAGAGACCTGACAACTATC reverse). RT-PCR was performed 
with iQ SYBR Green SuperMix (Bio-Rad, Hercules, Ca, USA) on an iQ5 thermocycler (Bio-
Rad). The reaction mixture was heated to 95°C for 3 min and amplifi cation was carried out 
for 40 cycles of 95°C for 30 sec, 60°C for 30 sec and 72°C for 1 min. The RT-PCR products 
were completely sequenced in both directions. Cycle-sequencing was performed using ABI 
PRISM Big Dye Terminators v 3.1 Cycle Sequencing Kit (Applied Biosystems, Foster city, 
Ca, USA) and sequencing products were run on an ABI PRISM 3730 Analyzer (Applied 
Biosystems). Mutation Surveyor (SoftGenetics LLC) software was used for analysis of the 
sequencing fi les.
Real-time quantitative RT-PCR analysis
Tumors, as well as dorsal and ventral skin were analyzed for Ldha, Pdk1, Glut1, Vegf-a by real-
time quantitative RT-PCR29 (primer pairs: TGTCTCCAGCAAAGACTACTGT forward, GACT-
GTACTTGACAATGTTGGGA reverse for Ldha; AGGCGGCTTTGTGATTTGTATTATG forward, 
TGTATTGTCTGTCCTGGTGATTTCG reverse for Pdk1; GGGCTGCCAGGTTCTAGTC forward, 
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CCTCCGAGGTCCTTCTCA reverse for Glut1; AAGGAGAGCAGAAGTCCCATGA forward, 
CACAGGACGGCTTGAAGATGT reverse for Vegf-a)30. -actin was used as the cellular 
housekeeping gene for normalization31. PCR reaction settings were 95°C for 3 min, then 40 
cycles at 95°C for 15 s and 58°C for 45 s; melting curves were also examined after each run.
Statistical tests
Kaplan Meier plots of tumor-free survival were analysed by χ2 tests (Graphpad Prism 3.0). 
Differences in pair-wise comparisons of tumor yields were analysed with Mann Whitney 
U tests, and Univariate Analysis of Variance was used to test simultaneously for group and 
gender effects on tumor yields (SPSS 12.0.1). Immunohistological scores and tumor staging 
was analyzed by pair-wise comparisons using Mann Whitney Rank Sum tests (SigmaPlot9.0/
SigmaStat3.1). Differences in p53 mutations between the diet groups were calculated by χ2 
tests. p<0.05 was considered to indicate a signifi cant difference.
Results
Response to diets
Animals in the 4 groups showed no differences in weight, and gained weight from the start 
of the experiment up to 16 weeks (control males from 30.0 ± 2.4 g [±SD] to 33.8 ± 2.9 g; 
females from 25.5 ± 1.6 to 27.9 ± 1.8 g). Blood levels of Rapa (33 ± 11 ng/ml, n=6) and MMF 
(mycophenolic acid at 2.9 ± 0.8 mg/l, n=3) were measured after 1 week on food containing 
the drugs, and were similar to those previously reported26.
Tumors
The animals showed no signs of sunburn throughout the experiment. This regimen of 
daily UV exposure of hairless mice was found to induce endophytic tumors which grow 
out to carcinomas28. Benign papillomas (exophytic – often pedunculated – caulifl ower-like 
tumors) were a small minority (<10%). These earlier fi ndings were confi rmed by pathology 
on tumors from the different groups. In summary, almost all tumors larger than 4mm were 
(invasive) SCC, whereas a substantial proportion of smaller tumors were SCC precursors, 
e.g. in situ carcinomas (Figure 1). No basal cell or spindle cell carcinomas were found. 
Papillomas were not included in the analyses of tumor induction.












































Figure 1: Histopathology of tumors smaller and larger than 4 mm in diameter; quartets of bars 
representing control (white bar), MMF (light gray), Rapa (black), and Rapa/MMF (dark gray) 
groups.
Tumor latency times
Figure 2 shows the tumor-free survival in the 4 different diet groups with tumor detection 
threshold set at 4 different diameters: minimal perceptible at a few tenths of a mm, 1 mm, 
2mm and 4mm. No differences were evident between the four groups for tumors with 
diameters up to 1mm. For tumors 2mm, the Rapa group clearly showed an increase in the 
time of tumor-free survival (p=0.0025 when compared with control). And for tumors 4mm 
the differences between the four groups are very distinct, with the control group developing 
the tumors most rapidly (with a median latency time, tm,of around 125 days), followed 
by the MMF group (tm=140 d, not signifi cantly different from controls), the MMF/Rapa 
group (tm=170 d, p=0.0004 vs controls), and, lastly, the Rapa group (tm=190 d, p=0.0021 vs 
controls); i.e., the Rapa group showed a delay of about 50% when compared to the control 
group. No overall differences in latency times between males and females were detected 
(p=0.34).
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Tumor multiplicity
Aside from how quickly a fi rst tumor appears, the number of tumors that an individual 
mouse develops is an important measure of severity. And, with small experimental groups 
like in the present study (n=10-12), counting the number of tumors increases the numerical 
strength of the analysis. The average number of tumors per mouse is referred to as ‘tumor 
yield’. These yields in the 4 different diet groups are depicted in Figure 3 with the threshold 
for tumor detection set at 4 different diameters: either minimal perceptible at a few tenths 
of a mm, 1mm, 2mm or 4mm (i.e. all tumors with diameters at or over the threshold were 
counted).
With the tumor detection threshold set at minimal perceptible lesions no discernible 
differences were observed up to 130 days. For tumors 1 mm there was a signifi cant 
difference at 139 days between the Rapa group and the control group (10.4 vs 19.2 tumors/
mouse, p=0.003). For tumors 2mm there was an even larger relative difference at that time 
point (1.6 vs 6.9 tumors/mouse, p=0.002) and at subsequent time points. The yields of 
the largest tumors (4mm) showed the clearest differences. At day 202 the Rapa group had 
developed signifi cantly fewer large tumors than the control group (1.6 vs 4.5 tumors/mouse, 
p=0.005), as did the Rapa/MMF combination group (1.8 vs 4.5 tumors/mouse, p=0.007). 
MMF appeared to have little effect as there was only a minor difference between the control 
group and the MMF group (4.5 and 3.6 tumors/mouse, respectively, n. s.), and virtually 
no difference between the Rapa and Rapa/MMF groups (1.6 and 1.8 tumors/mouse, n. s.). 
Again, no overall differences were found between males and females in tumor yields (for 
diameters 1mm p=0.35 at day 139, and 4mm p=0.89 at day 202). 
Angiogenesis and Vegf-a staining
Although it has been shown that the outgrowth of implanted tumors can be hampered by 
an anti-angiogenic effect of Rapa or MMF16, 17, 26, we could not detect any differences in the 
density of vessels in the tumor samples from the different groups (either by counting the 
number of vessels or by quantifying vessel endothelial cells stained with CD34; data not 
shown). Like in the tumor implants, we did, however, observe signifi cantly less expression 
of Vegf-a in the tumor cells from the Rapa group (Figure 4). The tumor stroma, on the other 
hand, did not show any difference in Vegf-a staining (data not shown). Interestingly, at 
this advanced stage of tumor growth (diameters >2-4 mm) we could not detect any clear 
reduction by Rapa in the levels of activated mTor effector proteins (phospho-S6 ribosomal 
protein, nuclear 4Ebp1 and Hif-1α; data not shown) which showed substantial variation in 
immunohistochemical staining between the tumors.



















































































































































































































































































































































Figure 4: Vegf-a expression in tumors: (A) typical examples of tumor sections histochemically 
stained for Vegf-a; (B) graphical presentation of Vegf-a expression in tumors from the 4 
experimental groups; * p=0.005 vs control. 
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Mutation analysis of p53 in tumors
Mutations in p53 occur early in UV carcinogenesis and they show a UV signature, i.e., C to 
T transitions at dipyrimidine sites4. We inspected whether the immunosuppressants could 
have affected the p53 mutation spectrum by metabolic effects from Rapa, or by anti-oxidant 
effects or effects on purine synthesis from MMF. Figure 5 gives a graphical summary of 
percentages of UV signature mutations in p53 in tumors (>2mm) from the four experimental 
groups (table 1 gives a more detailed overview). The control group clearly showed the 
expected mutation pattern with predominantly UV signature mutations. The mutation 
spectrum from the MMF group showed no signifi cant change. But the Rapa group showed a 
clear reduction in percentage of UV signature mutations (39% vs an average of 90% in the 
other groups, p=0.007 by 2 test). The relative increase in G>T and T>G mutations could 
be caused by oxidative damage32, and the T>C transitions possibly originate from thymine 
glycols as oxidation products33. Interestingly, combining Rapa with MMF again produced a 












Figure 5: Graph of the percentage of UV signature mutations (C to T transition at dipyrimidine 
site) among the p53 mutations in tumors from the 4 experimental groups.
The Warburg effect
A possible source of reactive oxygen could be the mitochondria by effects of Rapa on 
the respiration of tumor cells. Tumors have been reported to have shifted their glucose 
consumption from oxidative phosphorylation to aerobic glycolysis to lactate, which is 
dubbed the Warburg effect and can be driven by Hif-1α34. We hypothesized that Rapa could 
reduce the Warburg effect by lowering the level of Hif-1 or by interfering with Hif-1 
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activation35, and thus enhance oxidative phorphorylation and the release of reactive oxygen 
species (ROS) from mitochondria. Therefore, we measured expression of Hif-1 target 
genes34: Glut1, Pdk1, Ldha, and Vegf-a, where Glut1 is a glucose transporter, Pdk1 blocks 
pyruvate’s entry into the Krebs cycle, and Ldha catalyses the conversion of pyruvate and 
NADH to lactate and NAD. We found no differences between mRNA levels from these genes 
in tumors taken from the Rapa and control groups, as shown in Figure 6. However, we did 
observe interesting differences between UV-exposed skin, unexposed skin and tumors. In 
contrast to Ldha and Vefg-a, both Glut1 and Pdk1 were upregulated in UV-exposed dorsal skin 
when compared to unexposed ventral skin. But in the tumors Glut1 and Pdk1 expression was 
low and Ldha and Vegf-a expression was high. These data do not refl ect any unison effect of 
Hif-1 on the expression of these four target genes.
Table 1: Mutation analysis of p53 in tumors
Mouse #. Tumor # Codon Mutation Amino acid Not UV-typical
Control  
1.1 62 ctcCga>ctcTga R>R/X  
1.2 82 gccCCt>gccTTt P>P/F  
1.3 124 tCt>tTt S>S/F  
2.1 142 tTg>tCg L>S/L 
2.1 149 cctCca>cctTca P> P/S  
3.1 149 cctCca>cctTca P>P/S  
2.2 210 tttCgc>tttTgc R>C  
3.2 210 tttCgc>tttTgc R>R/C  
4.1 210 tttCgc>tttTgc R>C  
1.2 238 tCc>tTc S>S/F  
3.2 239 tGc>tTc C>C/F 
5.1 270 gttCgt>gttTgt R>C  
1.2 270 gttCgt>gttTgt R>R/C  
1.3 270 gttCgt>gttTgt R>R/C  
3.1 275 tgcCct>tgcTct P>P/S  
1.1 373 tCt>tTt S>S/F  
Rapa  
6.1 110 ggcTtc>ggcCtc F>L/F 
7.1 142 ttGtgg>ttTtgg L>L/F 
8.1 210 tttCgc>tttTgc R>C  
9.1 239 tGc>tTc C>C/F 
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Mouse #. Tumor # Codon Mutation Amino acid Not UV-typical
9.1 247 cCt>cGt P>P/R 
7.1 261 aacCtt>aacTtt L>L/F  
10.1 262 cTg>cCg L>P/L 
10.1 267 tTt>tCt F>F/S 
7.1 270 gttCgt>gttTgt R>R/C  
11.1 272 tgTgcc>tgGgcc C>W/C 
11.1 275 cCt>cTt P>P/L  
12.1 275 cCt>cTt P>P/L  
10.2 intron4 AG mutant heterozyg. del. 
MMF  
13.1 149 cctCca>cctTca P>P/S  
14.1 210 tttCgc>tttTgc R>C  
13.2 210 tttCgc>tttTgc R>R/C  
15.1 210 tttCgc>tttTgc R>R/C  
13.2 270 gttCgt>gttTgt R>R/C  
13.3 270 gttCgt>gttTgt R>R/C  
16.1 275 tgcCct>tgcTct P>S  
16.2 275 tgcCct>tgcTct P>S  
14.1 294 tgcCct>tgcAct P>T/P 
14.1 307 acCtgc>acTtgc T>T/T  
MMF + Rapa  
17.1 77 accCct>accTct P>P/S  
18.1 92 tCt>tTt S>S/F  
19.1 95 cCt>cTt P>P/L  
20.1 109-110 ggCTtg>ggTGtg G>G, F>V/F 
18.2 149 cCa>cTa P>P/L  
21.1 155 gtcCgc>gtcTgc R>R/C  
19.2 175-176 caCCat>caTAat H>H, H>N/H 
23.1 210 tttCgc>tttTgc R>C  
21.1 261 aacCtt>aacTtt L>L/F  
18.1 270 gttCgt>gttTgt R>R/C  
22.1 270 gttCgt>gttTgt R>R/C  
21.2 275 tgcCct>tgcTct P>P/S  
19.1 275 tgcCct>tgcTct P>P/S  
19.2   heterozyg. splicemutant exon7-exon12 



























Figure 6: Expression of Vegf-a, Ldha, Glut1 and Pdk1 as target genes of Hif-1 in comparison to 
-actin in various tissue samples from Rapa-fed and control mice; error bars depict SEM (Rapa and 
control tumors, each n=9; UV-exposed skin from Rapa n=7 and control group n=4; unexposed 
control ventral skin n=3).
Discussion
In contrast to earlier fi ndings with azathioprine and cyclosporine9,10, the newer-age 
immunosuppressants Rapa and MMF did not enhance UV carcinogenesis. In the case of 
Rapa, it had the opposite effect of strongly impairing the development of large tumors 
(2mm). This impairment can be attributed to the known anti-tumor, or more specifi cally, 
anti-angiogenic effects of Rapa16,17. At dosages which maintained allogeneic heart grafts 
in mice, Rapa thus inhibited outgrowth of tumor implants whereas cyclosporine was 
found to enhance angiogenesis and strongly stimulate tumor outgrowth18. Rapa could 
even block the pro-angiogenic effect from cyclosporine. In the present study the inhibition 
of tumor outgrowth by Rapa appeared to be refl ected in a signifi cant reduction of Vegf-a 
positive tumor cells. However, the Vegf-a expression in tumor stroma did not appear to 
be signifi cantly reduced, which leaves the question whether tumor cells and stroma were 
equally important in releasing Vegf-a into the interstitial compartment. Interestingly, we did 
not fi nd any clear effect on the vasculature of tumors that grew in the Rapa-fed groups, but 
these tumors may be presumed to have been selected for their vascularisation and resistance 
to Rapa while those that lagged behind were most sensitive to the anti-angiogenic effect 
of Rapa. MMF was also reported to impair tumor growth and angiogenesis16, but its effect 
on tumor implants appeared to be highly variable, possibly owing to differences in bio-
availability of its metabolite mycophenolic acid19. This may correspond to the slight – but 
not signifi cant – delay in onset of tumors (2mm) we observed in the MMF-fed animals.
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Our data differ from those obtained by Duncan et al36 who found that Rapa (sirolimus) 
increased the number of tumors by about 50% at the end of the experiment in which Rapa 
treatment started 10 weeks after weekly UV exposures. They reported some effects of MMF 
and Rapa on malignancy and average tumor size, but not any dramatic reduction in the 
number of large tumors, like we report here. In a subsequent study the same group did 
report a reduction in the number of tumors when Rapa was given after 15 weeks of UV 
irradiation and irradiation was discontinued37; at that point the mice had already developed 
an average of about 5 tumors per animal. In contrast to our experiments, their experiments 
were not optimal to detect any effect on tumor onset. Their experimental protocols differed 
substantially from ours, not only in the timing UV exposures and administration of Rapa, 
but also in the route of applying Rapa, i.e. by i.p. injection. At effective immunosuppressive 
dosages (1.5 mg/kg/day), the effi cacy of Rapa against tumor growth was found to be much 
enhanced by regular release (continuous infusion) in comparison to a massive bolus dose 
delivered by injection (once every 3 days)38. 
The concept that immunosuppressive agents should, by their very nature, enhance UV-
induced skin carcinogenesis8-10 is not supported by the present experiment (nor by the 
aforementioned experiments in references 36 and 37). Our data show no enhancement at 
all from immunosuppressive dosages of MMF and Rapa, neither on early stages nor on late 
stages of tumor development. Early experiments did show some systemic effects on small 
tumors in hairless mice attributable to altered immunity: prior UV-driven induction of small 
tumors on a limited area of skin, speeded up later UV tumorigenesis in a distant, formerly 
shielded, area of skin39. It should, however, be noted that the immune effects involved 
in UV carcinogenesis are complicated: besides a UV-induced (transient) suppression of 
immunisation, there is also an induction of specifi c tolerance toward UV-induced tumors8, 
40-43. UV carcinogenesis was actually delayed in CD80/CD86 double null mice lacking in 
tolerance induction42. Although immune defi cient mice did develop skin tumors more 
rapidly upon UV exposure than their profi cient counterparts, these immune defi cient mice 
were found to develop the tumors even faster when they had been thymically-reconstituted44. 
Suppression of T cell-mediated immunity can, therefore, have differential and competing 
effects on UV carcinogenesis, including both inhibitory and enhancing effects. Whether 
the lack of effect of Rapa and MMF in the present experiments on UV induction of small 
tumors is due to a complete lack of immunogenicity of small tumors, or whether it is due 
to an ‘accidental’ cancelation of T cell-mediated effects, remains to be determined. Although 
UV-induced immunosuppression has been reported to be affected by estrogen receptor 
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signaling45, we have found no gender effect in our experiments, in agreement with an earlier 
report29.
P53 mutations appear to be involved in the earlier stages of tumor development27. Our 
suspicion that Rapa might selectively induce apoptosis in the p53-mutated cells, and 
thus slow down the rate at which tumors are initiated, is not supported by our data as we 
found no effect the onset of the smallest perceptible tumors (<1mm). To check further for 
local effects of the immunosuppressants on the epidermal cells that might have affected 
UV carcinogenesis (e.g. disturbed metabolism by Rapa) we investigated the p53 mutation 
spectrum of the tumors which is normally dominated by the UV signature mutations. We 
found a dramatic shift in the types of mutations in tumors from the Rapa-fed group. This 
shift could have been due to an increase in ROS. Rapa did not cause such a shift when 
combined with MMF, which may be attributable to the known anti-oxidant activity of MMF.46 
We investigated the expression of target genes of Hif-1 to ascertain whether the Warburg 
effect and its suppression by Rapa could be responsible for changes in oxidative stress in the 
tumors. Although we did not fi nd any effect of Rapa on the expression of these four marker 
genes, we did fi nd striking differences in their expression in skin depending on UV exposure 
and in the tumors. In UV-exposed skin, the Pdk1 expression was increased, which implies 
a block of pyruvate entry into the Krebs cycle, shutting down oxidative phosphorylation 
and associated ROS formation in the mitochondria. Moreover, the increase in Glut1 may 
be related to anti-oxidant effects by transport of vitamin C47. We found Ldha to be highly 
expressed in the tumors which indicated that the Warburg effect was probably operative as 
Ldha catalyzes the conversion of pyruvate to lactate. Since Pdk1 expression was low in the 
tumors from the control and Rapa groups, oxidative phosphorylation may also have been 
active in the tumors, which may thus have switched on both glucose-metabolizing pathways. 
In conclusion, the present experimental data show that immunosuppressants do not 
necessarily enhance UV carcinogenesis, and can even lower the tumor burden. It has been 
already demonstrated that Rapa can impair the outgrowth of tumor implants, but our data 
provide evidence of the same effect on primary skin carcinomas induced by chronic UV 
exposure. Clinical data are beginning to emerge that also point to a lowered cancer risk when 
immunosuppressive medication is switched to Rapa48-50. Hence, further experimentation 
is urgently called for to better understand the pro- and anti-carcinogenic effects of various 
immunosuppressants, and eventually, to apply adequate immunosuppressive regimens 
while minimizing the long-term carcinogenic risk in organ transplant recipients.
Early and late effects of the immunosuppressants rapamycin and mycophenolate mofetil on UV carcinogenesis  41
Acknowledgements
We would like to thank Astrid Schwend and Cornelia Michl for technical assistance with 
immunohistology. 
42  Chapter 2
References
1. Hiesse C, Rieu P, Kriaa F, Larue JR, Goupy C, Neyrat N, Charpentier B. Malignancy after renal 
transplantation: analysis of incidence and risk factors in 1700 patients followed during a 
25-year period. Transplant Proc 1997;29:831-3.
2. Fortina AB, Caforio AL, Piaserico S, Alaibac M, Tona, F, Feltrin G, Livi U, Peserico A. Skin 
cancer in heart transplant recipients: frequency and risk factor analysis. J Heart Lung 
Transplant 2000;19:249-5. 
3. Buell JF, Hanaway MJ, Thomas M, Alloway RR, Woodle ES. Skin cancer following 
transplantation: the Israel Penn International Transplant Tumor Registry experience. 
Transplant Proc 2005;37:962-3. 
4. De Gruijl FR. Skin cancer and solar UV radiation. Eur J Cancer 1999;35:2003-9.
5. Bavinck JN, De Boer A, Vermeer BJ, Hartevelt MM, van der Woude FJ, Claas FH, Wolterbeek 
R, Vandenbroucke JP. (1993) Sunlight, keratotic skin lesions and skin cancer in renal 
transplant recipients. Br J Dermatol 1993;129:242-9.
6. Hartevelt MM, Bavinck JN, Kootte AM, Vermeer BJ, Vandenbroucke JP. Incidence of skin 
cancer after renal transplantation in The Netherlands. Transplantation 1990;49:506-9.
7. Hardie IR, Strong RW, Hartley LC, Woodruff P, Clunie GJ. Skin cancer in Caucasian renal 
allograft recipients living in a subtropical climate. Surgery 1980;87:177-83
8. Fisher MS, Kripke ML. Systemic alteration induced in mice by ultraviolet light irradiation and 
its relationship to ultraviolet carcinogenesis. 1977. Bull World Health Organ 2002;80:908-
12
9. Reeve VE, Greenoak GE, Gallagher CH, Canfi eld PJ, Wilkinson FJ. Effect of immunosuppressive 
agents and sunscreens on UV carcinogenesis in the hairless mouse. Aust J Exp Biol Med Sci 
1985;63:655-65.
10. Kelly GE, Meikle W, Sheil AG. Effects of immunosuppressive therapy on the induction of 
skin tumors by ultraviolet irradiation in hairless mice. Transplantation 1987;44:429-34.
11. Kelly GE, Meikle W, Sheil AG. Scheduled and unscheduled DNA synthesis in epidermal 
cells of hairless mice treated with immunosuppressive drugs and UVB-UVA irradiation. Br J 
Dermatol 1987;117:429-40. 
12. Kelly GE, Meikle WD, Moore DE. Enhancement of UV-induced skin carcinogenesis by 
azathioprine: role of photochemical sensitisation. Photochem Photobiol 1989;49:59-65.
13. O’Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, McGregor JM, Walker 
SL, Hanaoka F, Karran P. Azathioprine and UVA light generate mutagenic oxidative DNA 
damage. Science 2005; 309:1871-4. 
14. Sugie N, Fujii N, Danno K. Cyclosporin-A suppresses p53-dependent repair DNA synthesis 
and apoptosis following ultraviolet-B irradiation. Photodermatol Photoimmunol Photomed 
2002;18:163-8.
15. Yarosh DB, Pena AV, Nay SL, Canning MT, Brown DA. Calcineurin inhibitors decrease DNA 
repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest 
Dermatol 2005;125:1020-5.
Early and late effects of the immunosuppressants rapamycin and mycophenolate mofetil on UV carcinogenesis  43
16. Tressler RJ, Garvin LJ, Slate DL. Anti-tumor activity of mycophenolate mofetil against 
human and mouse tumors in vivo. Int J Cancer 1994;57:568-73.
17. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke 
C, Farkas S, Anthuber M, Jauch KW, Geissler EK. Rapamycin inhibits primary and metastatic 
tumor growth by antiangiogenesis:involvement of vascular endothelial growth factor. Nat 
Med 2002;8:128-35. 
18. Koehl GE, Andrassy J, Guba M, Richter S, Kroemer A, Scherer MN, Steinbauer M, Graeb 
C, Schlitt HJ, Jauch KW, Geissler EK. Rapamycin protects allografts from rejection 
while simultaneously attacking tumors in immunosuppressed mice. Transplantation 
2004;77:1319-26.
19. Koehl GE, Wagner F, Stoeltzing O, Lang SA, Steinbauer M, Schlitt HJ, Geissler EK. 
Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable 
antitumor effects in vivo, possibly related to bioavailability. Transplantation 2007;83:607-
14.
20. Wan YS, Wang ZQ, Shao Y, Voorhees JJ, Fisher GJ. Ultraviolet irradiation activates PI 3-kinase/
AKT survival pathway via EGF receptors in human skin in vivo. Int J Oncol 2001;18:461-6.
21. Lang SA, Gaumann A, Koehl GE, Seidel U, Bataille F, Klein D, Ellis LM, Bolder U, Hofstaedter 
F, Schlitt HJ, Geissler EK, Stoeltzing O. Mammalian target of rapamycin is activated in 
human gastric cancer and serves as a target for therapy in an experimental model. Int J 
Cancer 2007;120:1803-10.
22. Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J,Cordon-Cardo C, 
Simon MC, Rafi i S, Pandolfi  PP. PML inhibits HIF-1alpha translation and neoangiogenesis 
through repression of mTOR. Nature 2006;442:779-85.
23. Amornphimoltham P, Patel V, Leelahavanichkul K, Abraham RT, Gutkind JS. A retroinhibition 
approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer. 
Cancer Res 2008;68:1144-53.
24. Knaup KX, Jozefowski K, Schmidt R, Bernhardt WM, Weidemann A, Juergensen JS, Warnecke 
C, Eckardt KU, Wiesener MS. Mutual regulation of hypoxia-inducible factor and mammalian 
target of rapamycin as a function of oxygen availability. Mol Cancer Res 2009;7:88-98.
25. Huang S, Liu LN, Hosoi H, Dilling MB, Shikata T, Houghton PJ. p53/p21(CIP1) cooperate in 
enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. 
Cancer Res 2001;61:3373-81. 
26. Koehl GE, Gaumann A, Zuelke C, Hoehn A, Hofstaedter F, Schlitt HJ, Geissler EK. 
Development of de novo cancer in p53 knock-out mice is dependent on the type of long-
term immunosuppression used. Transplantation 2006;82:741-8.
27. Rebel H, Kram N, Westerman A, Banus S, van Kranen HJ, de Gruijl FR. Relationship between 
UV-induced mutant p53 patches and skin tumours, analysed by mutation spectra and by 
induction kinetics in various DNA-repair-defi cient mice. Carcinogenesis 2005;26:2123-30.
28. De Gruijl FR, van der Meer JB, van der Leun JC. Dose-time dependency of tumor formation 
by chronic UV exposure. Photochem Photobiol 1983;37:53-62.
29. El Filali M, Homminga I, Maat W, van der Velden PA, Jager MJ. Triamcinolone acetonide and 
anecortave acetate do not stimulate uveal melanoma cell growth. Mol Vis 2008;14:1752–9.
44  Chapter 2
30. Huang Y, Hickey RP, Yeh JL, Liu D, Dadak A, Young LH, Johnson RS, Giordano FJ. Cardiac 
myocyte-specifi c HIF-1alpha deletion alters vascularization, energy availability, calcium 
fl ux, and contractility in the normoxic heart. FASEB J 2004;18:1138-40.
31. Gilsbach R, Kouta M, Bonisch H, Bruss M. Comparison of in vitro and in vivo reference 
genes for internal standardization of real-time PCR data. Biotechniques 2006;40:173–7.
32. De Gruijl FR, van Kranen HJ, Mullenders LH. UV-induced DNA damage, repair,mutations 
and oncogenic pathways in skin cancer. J Photochem Photobiol B 2001;63:19-27.
33. Basu AK, Loechler EL, Leadon SA, Essigmann JM. Genetic effects of thymine glycol: 
site-specifi c mutagenesis and molecular modeling studies. Proc Natl Acad Sc. U S A 
1989;86:7677–81.
34. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 
2008;8:705-13.
35. Land SC, Tee AR. Hypoxia-inducible factor 1alpha is regulated by mammalian target of 
Rapamycin (mTOR) via an mTOR signalling motif. J Biol Chem 2007;282:20534-43.
36. Duncan FJ, Wulff BC, Tober KL, Ferketich AK, Martin J, Thomas-Ahner JM, Allen SD, 
Kusewitt DF, Oberyszyn TM, Vanbuskirk AM. Clinically relevant immunosuppressants 
infl uence UVB-induced tumor size through effects on infl ammation and angiogenesis. Am 
J Transplant 2007;7:2693-703.
37. Wulff BC, Kusewitt DF, VanBuskirk AM, Thomas-Ahner JM, Duncan FJ, Oberyszyn TM. 
Sirolimus reduces the incidence and progression of UVB-induced skin cancer in SKH mice 
even with co-administration of cyclosporine A. J Invest Dermatol 2008;128:2467-2473. 
38. Guba M, Koehl GE, Neppl E, Doenecke A, Steinbauer M, Schlitt HJ, Jauch KW, Geissler EK. 
Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. 
Transpl Int 2005;18:89-94.
39. De Gruijl FR, van der Leun JC. Follow up on systemic infl uence of partial pre-irradiation on 
UV-tumorigenesis. Photochem Photobiol 1983;38:381-3.
40. Kripke ML, Fisher MS. Immunologic parameters of ultraviolet carcinogenesis. J Natl Cancer 
Inst 1976;57:211-5. 
41. Spellman CW, Daynes RA. Modifi cation of immunological potential by ultraviolet radiation. 
II. Generation of suppressor cells in short-term UV-irradiated mice. Transplantation 
1977;24:120-6.
42. Loser K, Scherer A, Krummen MB, Varga G, Higuchi T, Schwarz T, Sharpe AH, Grabbe S, 
Bluestone JA, Beissert S. An important role of CD80/CD86-CTLA-4 signaling during 
photocarcinogenesis in mice. J Immunol 2005;174:5298-305. 
43. Moodycliffe AM, Nghiem D, Clydesdale G, Ullrich SE. Immune suppression and skin cancer 
development: regulation by NKT cells. Nat Immunol 2000;1:521-5. 
44. Norbury KC, Kripke ML. Ultraviolet carcinogenesis in T-cell-depleted mice. J Natl Cancer 
Inst 1978;61:917-21. 
45. Widyarini, S., Domanski, D., Painter, N. and Reeve, V.E. Estrogen receptor signaling 
protects against immune suppression by UV radiation exposure. Proc Natl Acad Sci U S A 
2006;103:12837-42.
Early and late effects of the immunosuppressants rapamycin and mycophenolate mofetil on UV carcinogenesis  45
46. Krotz F, Keller M, Derfl inger S, Schmid H, Gloe T, Bassermann F, Duyster J, Cohen CD, 
Schuhmann C, Klauss V, Pohl U, Stempfl e H, Sohn H. Mycophenolate Acid Inhibits 
Endothelial NAD(P)H Oxidase Activity and Superoxide Formation by a Rac1-Dependent 
Mechanism. Hypertension 2007;49:201-8.
47. Sagun KC, Carcamo JM, Golde DW. Vitamin C enters mitochondria via facilitative glucose 
transporter 1 (Glut1) and confers mitochondrial protection against oxidative injury. FASEB 
J 2005;19:1657-67.
48. Stallone, G., Schena, A., Infante, B., Di Paolo, S., Loverre, A., Maggio, G., Ranieri, E., Gesualdo, 
L., Schena, F.P. and Grandaliano, G. Sirolimus for Kaposi ‘s sarcoma in renal0transplant 
patients. N Engl J Med 2005;352:1317-23.
49. Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, Claesson K, Stallone 
G, Russ G, Rostaing L, Kreis H, Burke JT, Brault Y, Scarola JA, Neylan JF. Sirolimus therapy 
after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. 
J Am Soc Nephrol 2006;17:581-9.




Rapamycin impairs UV induction of 
mutant-p53 overexpressing cell clusters 
without affecting tumor onset
Voskamp P, Bodmann CA, Rebel HG, Koehl GE, Tensen CP, Bouwes Bavinck JN, 
El Ghalbzouri A, Van Kranen HJ, Willemze R, Geissler EK, De Gruijl FR
Int J Cancer. 2011 Dec 9. doi: 10.1002/ijc.27391. [Epub ahead of print]
48  Chapter 3
Abstract 
Because of its anti-tumor effect, the immunosuppressant rapamycin holds great promise 
for organ transplant recipients in that it may lower their cancer risk. In a mouse model 
we showed previously that rapamycin inhibits the outgrowth of primary skin carcinomas 
induced by UV radiation. However, the tumors that did grow out showed an altered p53 
mutation spectrum. Here, we investigated whether this shift in p53 mutations already 
occurred in the smallest tumors, which were not affected in onset. We found that rapamycin 
did not alter the mutational spectrum in small tumors and in preceding microscopic clusters 
of cells expressing mutant-p53. However, rapamycin did reduce the number of these cell 
clusters. As this reduction did not affect tumor onset, we subsequently investigated whether 
rapamycin merely suppressed expression of mutated p53. This was not the case, as we could 
demonstrate that switching from a diet with rapamycin to one without, or vice versa, did not 
affect the number of existing mutant-p53 expressing cell clusters. Hence, rapamycin actually 
reduced the formation of mutant-p53 cell clusters. In wild-type and p53-mutant mice we 
could not measure a signifi cant enhancement of UV-induced apoptosis, but we did observe 
clear enhancement in human skin equivalents. This was associated with a clear suppression 
of HIF1 accumulation. Thus, we conclude that rapamycin reduces the formation of mutant-
p53-expressing cell clusters without affecting tumor onset, suggesting that tumors grow out 
of a minor subset of cell clusters, the formation of which is not affected by rapamycin.
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Introduction
Organ transplant recipients have a high incidence of skin cancers. An important risk 
factor for skin cancer development appears to be immunosuppressive therapy, especially 
when the conventional immunosuppressants cyclosporine and azathioprine are used1, 2. 
The immunosuppressive drug rapamycin (sirolimus) has now been used for several years 
in immunosuppressive therapies in organ transplant recipients and appears promising in 
reducing the post-transplant cancer risk3. 
Rapamycin is an immunosuppressant that exerts its effect through inhibition of the 
mammalian target of rapamycine (mTOR) pathway, which is a mechanism of action entirely 
different from that of other immunosuppressants. Rapamycin has been shown to inhibit 
the mTORC1 complex, preventing p70s6k from becoming activated and thereby preventing 
S6 phosphorylation and by inhibiting 4EBP1, both processes affecting protein synthesis 
differently4. Furthermore, rapamycin has been shown to inhibit hypoxia-induced HIF1 
and VEGF expression5. HIF1 accumulates in nuclei of keratinocytes after UV irradiation in a 
biphasic manner, peaking in protein expression at 10-24 hours after irradiation6. Rapamycin 
increased apoptosis in murine embryo fi broblasts defi cient in p53 after serum depletion, 
while infection with Ad-p53 completely protected against rapamycin-induced apoptosis by 
inducing G1 cell cycle arrest7.
Recent studies indicate that rapamycin decreases the rate at which skin malignancies 
develop. A switch to rapamycin therapy in a small study reduced the development of (pre)
malignancies and nonmelanoma skin cancer in renal transplant patients3. Studies using 
hairless mice have also shown inhibiting effects of rapamycin on tumors; it reduced the 
incidence and progression of UV-induced skin cancer8. In a previous study by our group 
rapamycin did not affect the onset of UV-induced skin tumors <1mm, but showed decreased 
numbers of tumors >2mm (chapter 2). The latter study also showed that UV-induced tumors 
>2mm from rapamycin-fed mice harbor a different mutational spectrum of the p53 gene, 
with less UV signature mutations (i.e. C to T transitions at dipyrimi dine sites), compared 
with tumors from control-fed mice. 
Hence, rapamycin does not affect tumor onset but it decreases development of large tumors, 
indicating that a specifi c subset of small tumors is not inhibited in growth by rapamycin. 
Increased levels of reactive oxygen species have been described in yeast to inhibit binding 
of rapamycin to its target TORC1, leading to rapamycin insensitivity10. The mechanism for 
rapamycin insensitivity may thus be linked to the altered p53 mutational spectrum. This 
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led us to the hypothesis that the altered p53 mutational spectrum occurs late in tumor 
development and is not present in the majority of small tumors or precursor lesions. UV-
induced skin tumors >2mm typically harbor multiple p53 mutations (chapter 2). The altered 
mutational spectrum may therefore appear late in tumor development without affecting 
tumor onset which is associated with early p53 mutations, or a minor subset with deviant 
p53 mutations may escape inhibition by rapamycin early-on in tumor development. To test 
this hypothesis on a shift in types of p53 mutations we have determined p53 mutations 
in tumors <2mm and clusters of mutant-p53 overexpressing cells (mut-p53 cell clusters) 
which arise in the skin after repeated UV exposure and are generally regarded as skin tumor 
precursors11-14. 
In performing this experiment we found that the number of mut-p53 cell clusters was lower in 
rapamycin-fed mice than in control mice. The apparent discrepancy between the reduction in 
mut-p53 cell clusters and unaltered tumor onset led to the hypothesis that rapamycin either 
decreases expression of the p53 protein or acts in a pro-apoptotic manner on mut-p53 cell 
clusters. A possible effect on expression of mutant p53 was tested by switching between diets 
with and without rapamycin, which would also demonstrate whether any disappearance of 
mut-p53 cell clusters is associated with apoptosis. A possible effect on UV-induced apoptosis 
was further studied in (conditional) mutant(P275S) p53 knock-in mice and wild-type mice, 
and more extensively in human skin equivalents. In this investigation we have identifi ed 
the disparate effects of rapamycin in successive stages of UV carcinogenesis, demonstrating 
that local effects in the skin culminating in mutant p53-expressing cell clusters need not be 
predictive of tumor onset.
Materials and methods
SKH1 mouse model
SKH-1 hairless mice (Charles River, Maastricht, The Netherlands) entered the experiment at 
8-16 weeks of age; both male and female mice were used. The animal room was illuminated 
with yellow fl uorescent tubes (Philips TL40W/16, Eindhoven, The Netherlands) that did not 
emit any measurable UV radiation. The animals were housed individually in Macrolon type 
1 cages (Techniplast, Bugguggiate, Italy) under a 12 h light-12 h dark cycle at 23°C. Chow 
was supplied in ample amounts (55-60 g/mouse/week), and drinking water was available ad 
libitum. Cage enrichment was absent to prevent shielding of the animals from UV exposure. 
All experiments were performed in accordance with legislation and approval of the medical 
center’s ethics committee.
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Groups on diets with admixture of rapamycin
To avoid repeated i.p. injections rapamycin was admixed to standard mouse chow resulting 
in physiologically relevant blood levels as described previously (chapter 2). For the present 
experiment ssniff GmbH (Soest, Germany) supplied the chow with rapamycin at 20 mg/
kg, which was stored in a cold room and renewed every month. A study was performed to 
determine the rapamycin blood levels after starting (t=0, 1, 2 and 3 days after start, n=7-15) 
and stopping (t=0, 1, 2, 3 and 7 days after stop, n=3-15) the rapamycin diet. Blood of the 
mice was taken retroorbially between 8 and 9 a.m., and was subsequently analyzed by the 
Department of Clinical Chemistry (University of Regensburg) by LC-MS/MS for rapamycin 
concentration. Two diet groups were formed: rapamycin (n=10) and a control group (n=16) 
fed the standard chow without admixtures. For 10 weeks the mice were kept on their assigned 
food, then, in some experiments, the groups switched foods, i.e. the rapamycin group was 
put on control food and vice versa. Before (t=0, n=4), and at different time points after 
switching food (t=1, 2, 3 and 7 days, n=3), mice were taken out of the experiment (fi gure 
3A). 
Mutant p53P275S/+ mice
Because both in humans and mice the human codon 278 has been proven a UVB exposure 
specifi c mutational hotspot, we have selected the murine equivalent p53P275S mutant 
for this study. The generation of this conditional point mutant p53 strain of mice was 
essentially as described for two other p53 point mutant mice with the p53R172H allele and 
the p53R270H allele15 and can be briefl y summarized as follows. The P275S point mutated 
allele was constructed by site-directed mutagenesis as described before16 and has been 
made conditional by the introduction of a LoxP-fl anked transcriptional STOP cassette into 
intron 1 of the p53 gene (fi gure 1). This Lox-STOP-Lox (LSL) cassette was kindly supplied 
by Dave Tuveson. Detailed characterization of the LSL cassette was provided elsewhere 
upon the creation of a conditional oncogenic allele of K-ras17. This conditional p53P275S 
allele (18.7 kb) was verifi ed by sequencing the entire construct (data not shown) and 
targeted into Ola129(E14) embryonic stem cells. Germline transmission was achieved in 
multiple clones and the presence of the STOP cassette in intron 1 and the presence of the 
P275S point mutation of these mice was determined by PCR (data not shown). After >5 
generations of backcrossing to a C57Bl6 background, p53P275S/+ mice were crossbred with 
EIIa-Cre deleter mice (both strains acquired from the Department of Human Genetics, 
LUMC, Leiden) yielding offspring with a mutant p53 allele (C>T mutation changing P to 
S in codon 275, the UV-mutational hotspot) and wild-type (wt) littermates. As this study 
is the fi rst to use the mice carrying the p53P275S a llele, we checked transcription of mutant 
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p53 mRNA in the EIIa-Cre/p53P275S mice. The epidermises of F2 experimental animals were 
checked on expression of mutant p53 after UV exposure by staining with PAb240, excluding 
a minority (n=3) of mosaic mice not expressing mutant-p53 in the epidermis. Thus, twelve 
wt mice and eight mutant-p53 mice contributed to the fi nal data. The mice were started on 
experimental diets (with or without rapamycin) for two weeks prior to UV irradiation. Mice 
were shaven one day prior to UV irradiation with 1.5MED (2250J/m2) or 3MED (4500J/m2). 
Forty-eight hours after irradiation mice were sacrifi ced and biopsies of the skin were taken. 
Part of each biopsy was snap-frozen in liquid nitrogen, with the other part being fi xed in 4% 
formaldehyde, dehydrated and embedded in paraffi n. Sections of the biopsies were stained 
for active caspase-3, p53 (CM5) and mutant p53 (Pab240).
Human Skin Equivalents (HSE)
Keratinocytes were isolated as described earlier18. In brief, surplus skin obtained from cosmetic 
surgery (obtained in accordance with the Dutch Law on Medical Treatment Agreement) was 
cut into small fragments and incubated overnight in dispase II (Roche Diagnostics, Almere, 
The Netherlands). Keratinocytes were isolated from the epidermis through incubation with 
trypsin at 37°C for 15 minutes. After trypsin inactivation, cells were fi ltered and cultured in 
keratinocyte medium at 37°C and 7.3% CO2 until sub-confl uency. Keratinocyte medium 
consisted of 3 parts Dulbecco’s modifi ed Eagle’s medium (DMEM, Gibco/Invitrogen, Breda, 
The Netherlands) and 1 part Ham’s F12 medium supplemented with 5% fetal bovine serum 
(FBS, HyClone/Greiner, Nürtingen, Germany), 0.5 mM hydrocortisone, 1 mM isoproterenol, 
0.1 mM insulin (Sigma-Aldrich, Zwijndrecht, The Netherlands), 100 U ml-1 penicillin and 
100 μg ml-1 streptomycin (Invitrogen, Breda, The Netherlands). For isolation of normal 
human dermal fi broblasts (NHDFs), human dermis was obtained by overnight incubation 
of fresh surplus skin from cosmetic surgery with dispase II. Fibroblasts were isolated from 
the dermis by incubation with a solution consisting of collagenase II (Invitrogen, Breda, 
The Netherlands) and dispase II (ratio 1:3) at 37°C for 2 hours. The cells were fi ltered, 
and cultured in fi broblast medium at 37°C and 5% CO2 until sub-confl uency. Fibroblast 
medium consisted of DMEM supplemented with 5% FBS, 100 U ml-1 penicillin and 100 μg 
ml-1 streptomycin. Passages 2-5 were used for the experiments. 
Full-Thickness Models (FTM) using rat-tail collagen were generated as described before18. 
In brief, 80 x 103 fi broblasts were seeded into acetic acid extracted rat-tail collagen. The 
fi broblast-populated matrices were cultured for a week in standard fi broblast medium. 
FTMs were seeded with 50 x 104 normal human epidermal keratinocytes in low passage 
per model. Cultures were incubated overnight in keratinocyte medium supplemented with 
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1% FBS, 53μM selenious acid, 10mM L-serine, 10μM L-carnitine, 1mM dL-a-tocopherol-
acetate, 100μg ml-1 ascorbic acid phosphate, 2.4 x 10-5 M bovine serum albumin and a lipid 
supplement containing 25mM palmitic acid, 15mM linoleic acid and 7mM arachidonic 
acid (Sigma-Aldrich, Zwijndrecht, The Netherlands). Culture medium was then replaced 
with supplemented keratinocyte medium as described above, except that serum was omitted 
and the concentration of linoleic acid was increased to 30 mM. The models were cultured 
air-exposed from this time onward. Medium was refreshed twice per week. After 2 weeks of 
air-exposed culture, the HSEs were processed for analysis.
Supplement/Chemicals
Rapamycin (Calbiochem, Canada) dissolved in absolute DMSO was supplemented to HSEs 
(0.1%) that were cultured for 11 days at the air-liquid interface. Rapamycin concentrations 
used were 10 or 100nM19, and were applied two days prior to UV irradiation.
UV-source
Mice: Six groups were started on their respective diets 1 week before subjecting them to 
a regimen of daily UV exposure. TL-12/40W tubes (Philips, Eindhoven, The Netherlands; 
54% output in UVB – 280 to 315 nm – and 46% output in UVA – 315 to 400 nm) were used 
for daily UV exposure. The lamps were mounted over the cages with grid covers to allow 
undisturbed exposure of the mice. The lamps were automatically switched on daily from 
12.30 to 12.50 h. The threshold dose for a sunburn reaction (minimal edemal dose, MED) 
in the hairless SKH-1 mouse was ~500J/m2 UV under these lamps. The lamps were dimmed 
both electronically and by insertion of perforated metal sheets to expose the mice daily to 
250 J/m2 of UV radiation (0.5 MED).
HSE: Skin models were exposed to UV irradiation from TL-12/20W tubes (Philips, Eindhoven, 
The Netherlands; 54% output in UVB – 280 to 315 nm – and 46% output in UVA – 315 to 
400 nm) at 0.28 mJ/cm2/sec. UV dosages ranged from 0 to 110 mJ/cm2 of which the higher 
dosages yield signifi cant apoptotic response. 
Mutant-p53 immunostaining in epidermal sheets
Within 24 hrs after the last irradiation, mice were sacrifi ced and 11 × 34 mm pieces of 
dorsal skin were excised and treated with a thermolysin solution, after which the epidermal 
sheet was separated. A modifi ed procedure of epidermal sheet preparation and subsequent 
immunostaining and analysis was used12. Pab240 antibody (Monosan) was used at a 1:250 
dilution, with secondary goat anti-mouse-biotin antibody (Dako) used at a 1:200 dilution. 
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P53 mutation determination
RNA extracted from tumors <2mm was converted to cDNA and used as a template to amplify 
and subsequently sequence the entire coding sequences of the p53 transcript as described 
previously (chapter 2). Immunostained epidermal sheets were dehydrated and immuno-
positive laser dissected mut-p53 cell clusters were lysed by proteinase K. After whole genome 
amplifi cation (Genomiphi V2, GE Healthcare) of the lysate the DNA was purifi ed by spin 
columns (DNeasy, QIAGEN, Venlo, The Netherlands) and served as template for PCR 
amplifi cation of exons 4 – 8 using previously described primers20. The PCR products were 
completely sequenced in both directions. 
Morphology and immunohistochemistry
Part of the HSEs were fi xed in 4% formaldehyde, dehydrated and embedded in paraffi n, 
whereas the other part was snap-frozen. For morphological analysis, 5μm sections were cut, 
deparaffi nized, rehydrated and stained with haematoxylin and eosin for analysis by light 
microscopy. For HIF1 staining, sections (5μm) were cut, deparaffi nized and rehydrated, 
and antigen retrieval was performed by boiling the sections in 0.1M citrate buffer (pH 
6.9) in an autoclave at 110oC for 10 minutes. Subsequent steps were performed with a CSA 
amplifi cation kit (Dako, ref 1500). For active-caspase-3 staining of HSE or mouse material, 
cryosections were cut (5μm), fi xed in methanol/acetone (1:1) for 10 minutes and incubated 
overnight with primary antibody (anti-active-caspase-3, Ab2302, Abcam, Cambridge, UK) 
at 4°C. Secondary antibody (goat anti-rabbit-biotin, BA1000, Vector, Burlingame, CA) was 
added for 1 hour at RT and sections were stained with avidin-biotin complex (Vectastain, 
Vector) incubated with AEC. For p53 staining of UV-exposed skin in mice, CM5 antibody 
(Monosan, Uden, The Netherlands) was used as described previously21. Deparaffi nized 
sections of skin tumors from a previous study (chapter 2) were stained for mutant-p53 with 
Pab240 antibody as described previously21.
Statistics
Differences in p53 mutational spectra between the diet groups were calculated by χ2 
test. Differences in the number of mut-p53 cell clusters were calculated using ANOVA. 
The Mann-Whitney test was used to calculate differences between percentages of cells of 
tumors expressing mutant p53. A P-value of <0.05 was considered as statistically signifi cant 
difference. All calculations were performed with SPSS 16.0.
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Results
Rapamycin alters the mutational spectrum of p53 late in tumor 
development
In addition to the earlier measured altered p53 mutational spectrum in tumors >2mm from 
rapamycin-fed mice (fi gure 2) (chapter 2), we investigated the p53 mutations in tumors 
<2mm of rapamycin-fed mice from the same experiment. In a new experiment, mut-p53 
cell clusters were induced in rapamycin-fed mice under the same conditions as the earlier 
study, and p53 mutations in mut-p53 cell clusters were determined. Of the p53 mutations 
in tumors <2mm, 80% (20 out of 25) were UV-type (i.e. C to T transition at dipyrimidine 
sites), and mut-p53 cell clusters contained 82% (9 out of 11) UV-type mutations (fi gure 2). 
Mut-p53 cell clusters and tumors have been previously described to harbor 79-89% UV-type 
mutations12, 13. These results show that the altered p53 mutational spectrum in rapamycin-

















Figure 2: Percentages of UV-typical mutations (C to T transition at a dipyrimidine site) are 
shown here in mut-p53 cell clusters (n=15), tumors <2mm (n=21) and tumors >2mm (n=7) of 
rapamycin-fed mice and (n=7) of control mice (two columns for tumors >2mm from chapter 2). 
The mutational spectrum is only altered in tumors >2mm in rapamycin-fed mice.
Rapamycin impairs induction of mut-p53 cell clusters 
In these experiments we observed fewer mut-p53 cell clusters in dorsal skin of rapamycin-
treated mice than of control mice (data not shown). This may either be caused by the 
suppressed expression of (mutant-)p53 protein, enhanced apoptosis, or by decreased 
formation of mut-p53 cell clusters. To gain more insight into the mechanism, we conducted 
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an experiment in which mut-p53 cell clusters were induced by daily UV exposure in 
rapamycin-fed and control mice. Mice were put on experimental diets one week before 
starting UV exposures. After 10 weeks the diets were switched between the two groups. At 
different time points after switching food (1 to 7 days) mice were sacrifi ced and numbers of 
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Figure 3: (A) Schematic presentation of the time course in the rapamycin diet cross-over experiment; 
daily UV exposure starts at t=0, dashed line depicts control diet and solid line diet with rapamycin, 
cross lines depict sampling points of skin to assess frequencies of mut-p53 overexpressing cell 
clusters. (B) rapamycin blood levels in mice started on chow containing rapamycin (solid line), 
and mice switching from rapamycin-containing chow to control chow (dashed line). (C) Numbers 
of mut-p53 cell clusters in epidermal sheets from mice after switching diet from rapamycin to 
control (dashed line) or control to rapamycin (solid line). Before switching the diets, mice were 
daily exposed to UV for 10 weeks. n=3-4 mice per group. Here, time point 0 refers to the time of 
switching diets. Error bars depict SEM.
We fi rst measured the blood levels of rapamycin after starting or stopping rapamycin diets. 
Twenty-four hrs after starting the rapamycin diet, the rapamycin concentration in blood had 
already reached plateau levels (~57 ng/ml). When the rapamycin diet was stopped, drug 
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blood levels decreased to 10% of plateau after 24 hours, and were below detection limits 
after seven days (fi gure 3B).
Next, the numbers of mut-p53 cell clusters were determined in the different groups. Mice 
that had started on rapamycin diet during 10 weeks of UV-irradiation (n=10) harbored fewer 
mut-p53 cell clusters than control mice (n=10, p=0.002) Feeding of rapamycin to control 
mice (carrying pre-induced mut-p53 cell clusters) did not signifi cantly change the numbers 
of mut-p53 cell clusters at any of the time points tested (fi gure 3C). Moreover, removal of 
rapamycin from the diet of mice did not signifi cantly change the number of mut-p53 cell 
clusters at any of the selected time points (fi gure 3C). 
Rapamycin does not affect the percentage of tumors with p53 mutations, 
but does increase the mut-p53 expression in small tumors
Since the development of mut-p53 cell clusters is inhibited by rapamycin without having 
an effect on onset of tumors (<1mm) (chapter 2), the question arises whether mut-p53 cell 
clusters are genuine precursors of skin tumors. To gain more insight in the mechanisms 
involved, we checked whether (a proportion of) skin tumors in rapamycin-treated mice 
originate from cells without p53 mutation (p53 mutation is not obligatory for tumor 
formation). Therefore, we determined the percentage of tumors <2mm that contained 
mutations in the p53 gene across the different groups from a previous study (chapter 2). 
Seventy-one percent (15 out of 21) of the tumors from mice on control diet, and 73% (11 out 
of 15) of the tumors from rapamycin-fed mice harbored p53 mutations. These percentages 
are in agreement with a previous study21 and show that the frequency of p53 mutations is 
not different in tumors from rapamycin fed mice compared with control mice.
Expression of mutated p53 in tumors <2mm was determined by immunohistochemical 
staining of tumor sections. Remarkably, a higher fraction of tumor cells expressed mutated 
p53 in tumors of rapamycin-fed mice (n=16 from 6 mice) than in tumors of control mice 
(n=10 from 6 mice): 74% vs 34%, respectively, p=0.003 (fi gure 4). Expression of mut-p53 
in tumors >2mm did not differ signifi cantly between rapamycin-fed and control mice (89%, 
n=6 vs 74%, n=5, respectively). 



























Figure 4: The fraction of mut-p53-expressing cells in tumors <2mm from rapamycin-fed mice 
is increased compared to the same size tumors from control mice. Staining of mutant p53 was 
performed on 10 and 16 tumors from six mice per group. Boxes depict upper and lower quartile 
and whiskers depict the minimum and maximum value.
Effect of rapamycin on active caspase-3 positivity after UV in wild-type 
and mutant-p53 mice
Using mice that harbor heterozygous mutations in the p53 gene (275P>S) and littermates 
that were wild-type for p53, we investigated the effect of rapamycin on UV-induced apoptosis 
in exposed epidermis. Mice were fed a diet with or without admixture of rapamycin for two 
weeks. Subsequent exposure to 2250 J/m2 (1.5MED for shaven mice) resulted in induction 
of the apoptosis marker, active caspase-3. Only mice with positive staining for mutant 
p53 were included in the analysis to exclude mice without cre-mediated activation of the 
mutant-p53 construct in the epidermis. The proportion of epidermal cells expressing active 
caspase-3 tended to be higher in wild-type mice (n=6) compared to mut-p53 mice (n=4) 
on control diet 48 hours after UV exposure (23% vs 15%, respectively, P>0.05). Rapamycin 
caused a slight but insignifi cant increase in apoptosis in wild-type mice (28%, n=6, vs 23%, 
n=6, respectively), whereas the increase in mutant p53 mice was two-fold, but still not 
signifi cant (34%, n=4, vs 15%, n=4, respectively). As the variability in staining for apoptosis 
was substantial in skin samples and between mice (SD between 5 and 20%), a two-fold 
increase in apoptosis was not signifi cant. Also, expression of p53 (wild-type and mutant) 
was determined by immunohistochemical analysis and found to be increased after UV 
irradiation in both mouse strains. There was no clear effect of rapamycin treatment on the 
fraction of cells overexpressing p53 in the irradiated skin (data not shown). The mutant p53 
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mice showed no baseline overexpression of mutant p53 in unirradiated (abdominal) skin, 
i.e. mutation of p53 did not directly lead to overexpression of the protein.
Rapamycin enhances apoptosis in human skin equivalents (HSEs) 
To assess the effect of rapamycin on apoptotic responses in human cells we performed a 
more elaborate dose-effect experiment using HSEs generated with cells obtained from two 
different human donors. The HSEs were cultured for 2 days in the presence or absence of 
10nM or 100nM rapamycin. Subsequently, HSEs were irradiated with different doses of UVB 
(0, 30, 60, 85 and 110 mJ/cm2), and 24 hours later HSEs were processed for assessing active 
caspase-3 by immunohistochemical analysis. The data shown in fi gure 5 clearly demonstrates 
that supplementation of 100nM (91 ng/ml) rapamycin to the cultures consistently results in 
an increased number of active caspase-3-positive cells in the basal layer of the HSEs at UV 
doses over 60 mJ/cm2 (fi gure 5A). In addition, the number of positive cells for this apoptotic 
marker differed between HSEs generated with keratinocytes of the two different donors 
(fi gure 5B). Similar effects were also observed with 10nM of rapamycin (data not shown).
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Figure 5: Effect of rapamycin on apoptosis in HSEs. (A) cross-section of an HSE treated with 
100nM rapamycin and 24 h after irradiation with 90 mJ/cm2 UV. The stained cells (arrows) 
are basal cells positive for the pro-apoptotic protein active-caspase-3. The dashed line indicates 
basement membrane. Scale bar=100 μm. (B) The percentage of positive (supra-) basal cells for 
active caspase-3 after UVB irradiation is increased in HSEs treated with 100nM rapamycin. Results 
of HSEs from two different donors are depicted. (active caspase-3+ cells in a HSE sample were 
counted in 2 stretches of 100 basal cells; spread in counts per HSE sample appeared to be within 
expected 95% confi dence interval, based on a simple binomial distribution, i.e. ± 10% around 
50% and ± 6% around 10% or 90%).
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Rapamycin inhibits HIF1 up-regulation in HSEs after UV irradiation 
Rapamycin has been shown to inhibit the accumulation of HIF1 in response to 
hypoxia22. To assess the effect of rapamycin on HIF1 induction after UV irradiation, 
we determined its expression after UVB irradiation using a dosage of 30 mJ/cm2 in HSEs 
supplemented with or without rapamycin. The results obtained demonstrate that HSEs 
treated with rapamycin do not show any nuclei positive for HIF1, while the majority 
of cells in control HSEs showed positive nuclei for this protein at 10 and 24 hrs after UV 
irradiation (fi gure 6A-C). The expression of HIF1 was also negative in untreated HSEs 1 
hr after UV irradiation, as shown in fi gure 6C. Having established that HIF1 expression
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Figure 6: Effect of rapamycin on HIF1 induction in HSEs after UV exposure (A) HIF1-stained 
cross section of HSE 10 hours after irradiation with 30 mJ/cm2 UV in the absence of rapamycin; 
(B) HIF1-stained cross section of HSE supplemented with 100nM rapamycin 10 hours after 
irradiation with 30 mJ/cm2 UV; (C) table on HIF1 staining at several time points after UV 
exposure in rapamycin-treated or mock-treated HSEs. (D) table on HIF1 staining at 24 hours 
after irradiation with different UV dosages in rapamycin-treated or mock-treated HSEs. 
Legend: -=<30% positive (supra-)basal nuclei; +=50-80% positive (supra-)basal nuclei; ++=>80% 
positive (supra-)basal nuclei. The dashed line indicates basement membrane. Scale bar: 50 m
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in HSEs after UV exposure is upregulated after 24 h, we determined the HIF1 expression 24 
h after exposing HSEs to higher UV doses (60, 85 and 110 mJ/cm2). The different UV doses 
all resulted in upregulated HIF1 expression in the control samples, whereas rapamycin-
treated HSEs showed fewer nuclei stained positive for HIF1 (fi gure 6D). In the rapamycin-
treated HSEs irradiated at 85 and 110 mJ/cm2, the staining was dispersed, possibly due to 
the high dose of UV irradiation that induced many disintegrated cells positive for active 
caspase-3. 
Discussion
As rapamycin-treated mice developed UV-induced skin tumors with an altered p53 
mutational spectrum, without affecting tumor onset (chapter 2), we speculated that this 
altered mutational spectrum emerges late in tumor development. Our results show that 
putative microscopic precursor lesions and early stage tumors indeed harbored a normal 
UV-related p53 mutational spectrum, and that the occurrence of an altered mutational 
spectrum is specifi c for large tumors. Since we found lower numbers of mut-p53 cell clusters 
in rapamycin-fed mice, we speculated that rapamycin either decreases expression of the p53 
protein or acts in a pro-apoptotic manner on mut-p53 cell clusters. Our results show that 
rapamycin does not decrease previously induced mut-p53 cell clusters, showing neither an 
effect on expression of mutant p53, nor any apoptosis in the clusters. From this we conclude 
that rapamycin truly inhibits the formation of these cell clusters, possibly by enhanced early 
apoptosis. Such an enhancement of UV-induced apoptosis by rapamycin was not signifi cant 
in mice in our experimental setup, but could be clearly demonstrated in more elaborate and 
controlled experiments in HSEs.
The type of p53 mutations in UV-induced squamous cell carcinomas (SCCs) in mice are 
normally predominantly of a UV-specifi c type with a C>T transition on a dipyrimidine 
site (UV signature mutation). In a previous study (chapter 2) our group has shown that 
SCCs >2 mm from rapamycin-treated mice displayed an altered mutational spectrum, with 
a minority of UV-typical mutations. Here we showed that this shift in the type of mutations 
was not present in mut-p53 cell clusters and skin tumors <2mm from mice treated with 
rapamycin. It can therefore be concluded that the deviant p53 mutations were either late 
events in the development of tumors or only a minor subset of small tumors with an altered 
mutational spectrum (e.g. tumors with high endogenous oxidative stress) was able to grow 
out into large tumors, explaining the lower yield of large tumors in rapamycin-fed mice.
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Numbers of mut-p53 cell clusters were lower in mice fed rapamycin after 10 weeks of UV 
irradiation when compared with control mice. The number of mut-p53 cell clusters was not 
altered after switching the diet without rapamycin to one with rapamycin, or visa versa. Since 
our study showed that the number of mut-p53 cell clusters was lower when rapamycin was 
present during UV exposure, and that the number of mut-p53 cell clusters was not decreased 
after introduction of rapamycin, it can be surmised that rapamycin does not suppress 
mut-p53 expression or force mut-p53 cell clusters into apoptosis, but genuinely inhibits 
the formation of mut-p53 cell clusters. This might be attributable to an enhancement of 
UV-induced apoptosis of DNA damaged cells, thus preventing (p53) mutation appearance 
(see below).
Tumor latency times in UV-irradiated hairless mice were not affected by rapamycin (chapter 
2), but rapamycin in the present study impaired formation of mut-p53 cell clusters. This is 
an interesting fi nding since previous studies have correlated tumor induction closely with 
that of mut-p53 cell clusters12, 23. The present study shows for the fi rst time that a drug 
can impair the development of mut-p53 cell clusters without affecting tumor onset. For 
various reasons mut-p53 cell clusters have previously been considered precursor lesions for 
skin tumors12, 21, an assumption that is challenged by this study. It is still likely that most 
SCCs develop out of mut-p53 cell clusters since mutation of the p53 gene appears to be a 
consistent early event in squamous cell carcinoma development, i.e. already present in a 
majority of precursor lesions and subsequently in a majority of SCCs11, 21. But it is now clear 
that numbers of the p53-mut cell clusters cannot be reliably used as indicator for tumor 
risk. Since the large majority of mut-p53 cell clusters do not develop into tumors12, the 
impaired induction by rapamycin may only affect a majority of mut-p53 cell clusters which 
are not genuine precursors of tumors (actinic keratoses and SCCs). Hypothetically, a small 
specifi c subset of mut-p53 cell clusters might not be inhibited by rapamycin, e.g. due to an 
additional oncogenic change, and constitute the sole true precursors of the tumors. However, 
this additional oncogenic change remains to be identifi ed and requires further study. 
The percentage of small tumors harboring a mutation in the p53 gene was not different 
between the mice on rapamycin and control diet, indicating that mutation of p53 remained 
an important early event in the tumors in the rapamycin-treated group. It should, however, 
be noted that the small tumors were harvested at the end of the experiment and the skin of 
mice harbored many mut-p53 cell clusters at that time. This would make it more likely for a 
tumor to start with a mutated p53 by chance, since many epidermal cells harbor a mutated 
p53 in that stage of the experiment. A higher fraction of tumor cells expressed mutated p53 in 
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tumors <2mm after rapamycin-treatment of mice, compared to the same small-sized tumors 
of control mice. Rapamycin had, however, no apparent effect on the tumor development 
at that stage. This difference in expression of mutant p53 between rapamycin-fed mice and 
controls was not observed in tumors >2mm. 
Rapamycin did not signifi cantly alter the apoptotic response or p53 expression in wild-
type mice or mice harboring a germline p53 mutation. After a single dose of UV the active 
caspase-3 positive cell fraction in the epidermis of skin cells from mice on rapamycin diet 
was higher than in mice on control diet, especially in mut-p53 mice, but these rapamycin 
effects were not signifi cant.. The variability in the staining for active caspase-3 (and 
p53) appeared to have prevented us from observing signifi cant increases by rapamycin. 
Nonetheless, in more elaborate and controlled experiments in HSEs we did fi nd a clear 
increase in UV-induced apoptosis by rapamycin. We found associated HIF1 accumulation 
in keratinocytes after UV exposure of human skin equivalents to be inhibited by rapamycin. 
Previously it has been shown that HIF1 is upregulated after hypoxia24 and UV irradiation6, 
25, and that rapamycin can prevent hypoxia-induced HIF1 accumulation22. Here we show 
a similar effect of rapamycin on UV-induced HIF1 accumulation. HIF1 has been reported 
to inhibit or induce apoptosis, depending on the cell type26, 27. Our data suggest that HIF1 
likely moderates UV-induced apoptosis, and that rapamycin neutralizes this HIF1 effect. 
Early rapamycin-enhanced apoptosis in UV-damaged cells may have reduced the number of 
p53-mut clusters that develop. Moreover, our previous fi nding that rapamycin inhibits the 
development of large tumors (chapter 2) might be attributable to attenuating the HIF1 
pathway, thereby impairing the rate at which small tumors grow.
A recent prospective, controlled, clinical trial showed that transplant recipients who were 
switched to rapamycin treatment had a reduced rate of (pre)malignancies and nonmelanoma 
skin cancer3. In relation to this trial, the present study shows that rapamycin affects specifi c 
processes that may play a role in skin tumorigenesis. 
To summarize, after UV irradiation apoptosis is increased and HIF1 accumulation is 
impaired in a human skin model. In our experimental setup we could however not measure 
such an effect of rapamycin on UV-induced apoptosis in freely moving mice, but rapamycin 
did reduce mut-p53 cell cluster formation in chronically UV-exposed mice. Although this 
rapamcyin-related reduction in mut-p53 cell clusters did not result in a reduced onset of 
tumors, rapamycin treatment did reduce the number of larger tumors. Besides providing 
insight on the precise impact rapamycin has on UV responses and UV carcinogenesis, 
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our data unexpectedly demonstrated that fewer mut-p53 cell clusters do not necessarily 
correspond with a reduced onset of tumors.
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Abstract
Immunosuppressive therapy is thought to cause the increased risk of nonmelanoma skin 
cancer in organ transplant recipients. Considering the different working mechanisms 
of immunosuppressants, we set out to investigate their effects on the sequence of events 
leading up to tumor formation, in particular whether early effects on apoptosis and the 
frequency of p53 mutations would be predictive of the risk of skin cancer development. 
To this end, we compared immunosuppressants (azathioprine, cyclosporine, tacrolimus, 
mycophenolate mofetil and rapamycin) in a human skin model for short term effects 
and in a hairless mouse model for long term effects on UV carcinogenesis. In human skin 
models rapamycin was shown to inhibit epidermal regeneration and to increase UV-induced 
apoptosis, whereas cyclosporine decreased apoptosis. These apoptotic effects appeared to 
correspond to changes observed in the frequency of clones of cells overexpressing mutant 
p53 in chronically UV-exposed skin of mice that had immunosuppressants admixed to 
their diets. Deep sequencing of the mutational hotspots of p53 (codons 270 and 275) in 
the UV-irradiated epidermis indicated, however, that none of the immunosuppressants 
affected the frequency of these hotspot mutations (in about 10% of epidermal cells). Only 
a minority of p53-mutated cells appeared to overexpress mutated p53. Rapamycin inhibited 
the outgrowth of tumors, and cyclosporine remarkably delayed the onset of tumors. Thus, 
we found that apoptosis and the frequency of p53 mutations were not predictive of the rate 
at which skin carcinomas occurred. Moreover, none of the dietary fed immunosuppressants 
enhanced the onset of tumors, suggesting that these immunosuppressive medications per se 
do not necessarily increase the risk of skin carcinomas.
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Introduction
Organ transplant recipients are at an increased risk of developing nonmelanoma skin cancer, 
especially squamous cell carcinomas (SCC), on sun-exposed body parts. In the Netherlands 
40% of renal transplant recipients develop skin cancer within 20 years after transplantation1. 
In Australia where sun exposure is higher, this percentage is substantially higher (70%)2. As 
in the general population, skin carcinomas in organ transplant recipients are clearly related 
to solar UV exposure3. Furthermore, the skin cancers that these patients develop tend to be 
more aggressive and recur more often than those in immunocompetent patients4.
From animal experiments it is known that most UV-induced skin carcinomas are antigenic 
and targeted by the immune system5. Therefore, the increased risk of developing skin cancer 
has long been regarded as an inescapable side effect of immunosuppression, which all 
transplant recipients are subject to in order to prevent rejection of the transplanted organ. 
More recently, it has become clear that some of the immunosuppressants commonly 
used can directly promote cancer growth and/or affect anti-tumorigenic responses such as 
apoptosis6-8.
There are several classes of immunosuppressive drugs used in transplantation practice which 
differ by their mechanism of action. One of the fi rst immunosuppressive drugs that allowed 
successful organ transplantation in humans is azathioprine (Aza). Its active metabolite 
6-mercaptopurine (6MP) inhibits de novo purine synthesis and the metabolite 6-thioguanine 
competes for incorporation into DNA as a pseudo-base, thereby disrupting normal DNA/RNA 
synthesis9. Mycophenolate mofetil (MMF) is a prodrug of mycophenolic acid (MPA) which 
acts as an immunosuppressant by inhibiting de novo purine synthesis, but more specifi cally 
than Aza. MPA inhibits the enzyme inosine-5’-monophosphate dehydrogenase (IMPDH) 
without the incorporation of pseudobases into the DNA10. The calcineurin inhibitors 
cyclosporine (CsA) and tacrolimus (Tac) were thought to act more specifi cally on immune 
cells than Aza. CsA functions as an immunosuppressant by inhibiting interleukin-2 (IL-2) 
gene transcription. It does so by binding to cyclophilin and thus inhibiting the phosphatase 
calcineurin in activation of the nuclear factor of activated T-cells (NFAT)11. Tac also inhibits 
calcineurin, but via binding to FK-binding protein 12 (FKBP12)11. The immunosuppressant 
rapamycin (Rapa) is a compound that also interacts with FKBP12, but the complex targets 
and inhibits the mammalian target of rapamycin (mTOR)12. mTOR is the central node in 
signaling pathways that control cell growth, proliferation and metabolism13. Since IL-2 
signals primarily through this pathway, T cell proliferation is reduced by mTOR inhibitors14.
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Some immunosuppressants have direct adverse effects on skin cells, which can contribute 
to carcinoma risk. CsA affects DNA repair6, 7, and Aza enhances DNA damage by 
photosensitization8. Experiments by Australian groups7, 15 have confi rmed that Aza and CsA 
speed up UV carcinogenesis in hairless mice. CsA enhances angiogenesis and outgrowth of 
tumor inoculations in a mouse model, whereas Rapa inhibits both processes16, 17. Indeed, 
both Rapa and MMF are interesting with regard to their anti-tumor effects, since they impair 
growth of tumor inoculations in mice17, 18 and Rapa inhibits de novo tumor development 
in a p53-null mouse model19. Recent research by our group has shown that Rapa increases 
apoptotic responses after UV irradiation in a human skin model (chapter 3). In a small 
randomized clinical trial, a switch to Rapa treatment was shown to decrease development 
of nonmelanoma skin cancers in organ transplant recipients21. A previous study by our 
group has shown that early oncogenic alterations in mutant p53-overexpressing cell clusters 
(mut-p53 cell clusters) occurred more frequently in the skin of renal transplant recipients 
using Aza, when compared to immunocompetent patients22. As these early oncogenic 
alterations are not immunogenic23, it is likely that Aza had direct local effects on skin cells. 
A recent publication by our group showed that Rapa-fed mice develop fewer mut-p53 cell 
clusters compared to control mice (chapter 3).
Considering these notable differences between immunosuppressants, we posed the 
question whether it would be feasible to lower the skin cancer risk in organ transplant 
recipients by minimizing the non-systemic local impact on the skin. We investigated 
this by comparing commonly used immunosuppressants in parallel in experimental 
human skin and mouse models, in contrast to most prior investigations which either 
only included some immunosuppressants or did not combine early and late effects in 
UV-induced skin carcinogenesis. First, we systematically compared the impact of different 
immunosuppressants on epidermis and responses to UV exposure in human skin equivalents. 
Subsequently, we linked these in vitro results to effects of the immunosuppressants on 
UV carcinogenesis in a hairless mouse model. Thus, we aimed to establish whether local 
effects of immunosuppressants on specifi cally UV-induced apoptosis and p53 mutations are 
predictive of the risk of skin cancer development.
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Materials and Methods
Human Skin Equivalents (HSE)
Generation of human skin equivalents was performed as described earlier24. In brief, 
keratinocytes and fi broblasts were isolated from surplus breast skin obtained from cosmetic 
surgery of two donors (obtained in accordance with the Dutch Law on Medical Treatment 
Agreement). 80 x 103 fi broblasts were seeded into acetic acid-extracted rat-tail collagen 
deposited on fi lter inserts (product no. 3414; Corning, Amsterdam, The Netherlands). The 
fi broblast-populated matrices were cultured for a week in standard fi broblast medium. These 
matrices were subsequently seeded with 5 x 105 low-passage normal human epidermal 
keratinocytes and incubated with keratinocyte medium. Medium was refreshed twice a 
week. After 2 weeks of air-exposed culture, the HSEs were processed for analysis.
Supplements/Chemicals
Immunosuppressants dissolved in absolute DMSO were added to the HSEs at physiologically 
relevant concentrations25, 26: Rapa (Calbiochem, San Diego, SA) at 10nM or 100nM, 6MP 
(Sigma-Aldrich, St. Louis, MO) at 50nM or 500nM, CsA (Sigma-Aldrich) at 100nM or 1μM, 
Tac (Calbiochem) at 100nM or 1μM and MPA (Sigma-Aldrich) at 1μM or 10μM, at 0.1%(v/v). 
6MP and MPA are used as they are the active metabolites of Aza and MPA, respectively10. 
For effects on morphology, HSEs were supplemented with immunosuppressants or DMSO 
(as vehicle control) during the air-exposed culture. For effects on the response after UVB 
irradiation, HSEs were supplemented with immunosuppressants for two days prior to UVB 
irradiation.
The mice
SKH-1 hairless mice (Charles River, Maastricht, The Netherlands) entered the experiment 
at 8-16 weeks of age; both male and female mice were used. The animals were housed 
individually under a 12 h light-12 h dark cycle at 23°C. Experimental chow was supplied 
in ample amounts (60 g/mouse/week), and drinking water was available ad libitum. Cage 
enrichment was absent to prevent shielding of the animals from UV exposure. All experiments 
were performed in accordance with legislation and approval of the center’s ethics committee 
for animal experiments.
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Groups on diets with admixtures of immunosuppressants
To avoid repeated i.p. injections or oral gavage application of the immunosuppressants, 
admixtures of the drugs to standard mouse chow were used (Sniff GmbH, Soest, Germany) 
(chapter 2). For CsA, MMF and Rapa dosages were used that resulted in long-term average 
blood levels in the mice that were similar to the high end average blood levels in renal 
transplant patients (CsA at 150 mg/kg: 800 ng/ml, MMF at 660 mg/kg: 2.9 μg/ml MPA, Rapa 
at 20 mg/kg: 50 ng/ml). Due to toxicity Tac and Aza were admixed at maximal long-term 
tolerable dosages (Tac 20 mg/kg: 3.2 ng/ml, Aza 30 mg/kg: sub-anaemic white blood cell 
count). Six diet groups were formed: Rapa (n=26), MMF (n=22), CsA (n=24), Tac (n=24), 
Aza (n=26) and a control group (n=26) fed the standard chow without admixtures. The 
tumorigenesis experiment was performed in three parts, 1) Rapa and CsA, 2) Aza and Tac, 
3) MMF, each with a control group on chow without admixture. No apparent differences in 
food intake and body weights were observed between the diet groups.
UVB irradiation
Mice: The six groups were started on their respective diets 1 week before subjecting them to 
a regimen of daily UV exposure. TL-12/40W tubes (Philips, Eindhoven, The Netherlands; 
54% output in UVB – 280 to 315 nm – and 46% output in UVA – 315 to 400 nm) were used 
for daily UV exposure. The lamps were mounted over the cages with grid covers to allow 
undisturbed exposure of the mice. The lamps were automatically switched on daily from 
12.30 to 12.50 h. The threshold dose for a sunburn reaction (minimal edemal dose, MED) 
in the hairless SKH-1 mouse was ~500J/m2 UV under these lamps. The lamps were dimmed 
both electronically and by insertion of perforated metal sheets to expose the mice daily to 
250 J/m2 of UV radiation (0.5 MED).
HSEs: Skin models were also exposed to UV irradiation from TL-12/20W tubes at 
0.28 mJ/cm2/sec.
UVA irradiation of azathioprine-fed mice
Pigmented C57BL/6 mice on a hairless background (acquired by two rounds of breeding 
C57BL/6 with SKH1) were put on Aza (n=12) or control diet (n=13) 1 week before subjecting 
them to a regimen of daily UV exposure. Cleo Professional S R tubes (Philips, Eindhoven, 
The Netherlands; 1.4% output in UVB – 280 to 315 nm – and 98.6% output in UVA – 315 
to 400 nm) were used for irradiation. MED was determined by exposing mice to 7, 14, 21 
or 28 kJ/m2 UV. Mice were daily irradiated at 14 kJ/m2 (1MED) in the UVA carcinogenesis 
experiment.
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Tumor assessment
The mice were inspected weekly for tumors which were registered for each mouse individually 
on maps (recording number, location, size and form). For presentation in a single graph of 
the tumor induction data in Kaplan-Meier plots, the three experiments were adjusted to 
equal median latency times in the control groups (a time shift of maximally 2 weeks, with 
an average of 8 days). Upon removal of animals from the experiment, tumors and normal 
skin were isolated for further analysis as described below. 
Epidermal sheet preparation and mutant-p53 immunostaining in 
epidermal sheets
For quantifi cation of mut-p53 cell clusters, four SKH1 mice were taken from each diet group 
after 4, 7, or 10 weeks of UV exposures. Within 24 h after the last irradiation, mice were 
killed and pieces of dorsal skin of 11 × 34 mm were excised and treated with a 100 μg/ml 
thermolysin solution, after which the epidermal sheet was separated. The procedure of 
epidermal sheet preparation and subsequent immunostaining and analysis, described 
elsewhere28, was followed with two modifi cations: antigen retrieval in 10mM citrate buffer 
in an autoclave at 5 min, 110°C and mutant-p53 antibody diluted 1:250 (Pab240, Thermo 
Fisher Scientifi c, Fremont, CA). A 1 to 2mm wide mid-dorsal strip of the epidermal sheets 
was collected per mouse and used for DNA isolation (QIAamp, QIAGEN, Venlo, The 
Netherlands). Counts of mut-p53 positive cell clusters outside the range of 6-fold over or 
under the median (in cohorts of 4 mice) were rejected as outliers (with the exception of “0” 
if the lower limit was <1) to produce fi gure 2; this led to exclusion of 9 of 84 measurements 
from this graph. However, none of the measurements were excluded from statistical tests 
(see below).
P53 mutation hotspot PCR and deep sequencing
DNA from the murine epidermal strips of four mice per group was mixed equimolarly and 
used in a PCR reaction amplifying the p53 gene from codon 263 to 276, co ntaining the 
mutational hotspots at codons 270 and 275. The forward primer contained a sequence-
specifi c part and an adapter sequence at the 5’ end of the primer. The reverse primers were 
unique for each group containing a sequence-specifi c part, an index sequence, and an 
adapter sequence (supplementary table 1). Primers were HPLC-purifi ed (Integrated DNA 
technologies, Coralville, IA). PCRs were performed using high fi delity Phusion enzyme 
(Finnzymes, Vantaa, Finland) in a volume of 40 μl with the following program: 98°C for 
30 sec, then 28 cycles of 98°C for 10 sec, 64°C for 15 sec, 72°C for 15 sec, closing the 
program with 72°C for 10 min. PCR products were run on a 1.8% agarose gel, and stained 
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with Sybr Gold (Invitrogen), after which bands containing the amplicons were excised on 
a Dark Reader not emitting UV (Clare Chemical Research, Dolores, CO) and purifi ed using 
QIAquick (QIAGEN) spin columns. Amplicons were analyzed in one lane of an Illumina 
Sequencer HiSeq2000 (Illumina, San Diego, CA). Reads were fi ltered for high quality reads 
containing only bases that were called with a minimal fi delity of 99.9% (phred-score 30). 
Index sequences were used to distinguish the different samples. For the numbering of 
the bases, the p53 transcript with ID ENSMUST00000108658 from Ensembl was used as 
reference.
Histology and immunohistochemistry
Biopsies were fi xed in 4% formaldehyde, dehydrated and embedded in paraffi n or snap-
frozen in liquid nitrogen. Stainings for keratin 10 (K10), keratin 16 (K16), keratin 17 (K17) 
and Ki-67 were performed on formalin-fi xed and paraffi n-embedded sections (5μm) of 
skin models, mouse skin or tumors. Immunohistochemical analysis of active caspase-3 was 
performed using frozen sections (5μm), which after sectioning were fi xed in methanol/
acetone (1:1) for 10 minutes. Haematoxylin and eosin (H&E) staining was performed on 
deparaffi nized sections for tumor staging. Staging of tumors from each group was performed 
blinded by a pathologist (Dr. A. Gaumann, University of Regensburg, Germany) who is 
experienced in mouse and human pathology, including diagnosis of actinic keratoses as 
proper precursors of squamous cell carcinomas. Antigen retrieval for paraffi n-embedded 
sections was performed by autoclaving the sections in 10mM citrate buffer (pH 6.0) for 
10 minutes at 110°C. The primary antibodies used for immunohistochemistry are listed 
in supplementary table 2. After overnight incubation with the primary antibody at 4°C, 
sections were stained using standard protocols with AEC.
Estimate of proliferation index
The percentage of Ki-67 positive nuclei in the basal and immediate supra-basal layer was 
used to determine the proliferation index. A minimum of 100 cells were counted using light-
microscopy in three different regions in each section.
Statistical tests
Kaplan Meier plots of tum or-free survival were tested for differences by 2 statistics 
(Graphpad Prism 5.0). Differences in tumor yields were analyzed with randomized block 
one-way ANOVA, with Bonferroni as post-hoc test (Graphpad Prism 5.0). Differences in 
number of mut-p53 cell clusters per treatment (without outlier removal) were calculated in 
a general linear model multivariate analysis with least signifi cant difference as post-hoc test. 
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Differences in Ki-67 positive cell percentages in HSEs were calculated with one-way ANOVA 
and Dunett as post-hoc test. Differences in active-caspase 3 positive cell fractions in HSEs 
were calculated with a one-way ANOVA and Bonferroni as post-hoc test. P<0.05 was taken 
to indicate a signifi cant difference. SPSS 16.0 was used for all statistical analyses, except for 
the tumor free-survival and yield analyses. 
Results
Rapamycin affects epidermal regeneration in HSE
In a human skin equivalent (HSE) the effects of immunosuppressive drugs on epidermal 
regeneration were studied. HSEs were cultured with immunosuppressants added to the 
medium for two weeks: Rapa, Tac, MPA, 6MP, CsA or DMSO (vehicle). The skin models 
cultured in the presence of Rapa (10 and 100nM) showed a much reduced epidermal 
regeneration; the number of cell layers in control models was 7 to 8, whereas in the 
Rapa-treated models 3 to 4 layers were formed (fi gure 1). Rapa treatment resulted in a 
decreased proliferation index (22% with 100nM Rapa, and 11% with 10nM Rapa versus 
43% with DMSO), indicating decreased proliferation (p<0.05, supplementary fi gure 1). 
Immunohistochemical staining for hyperproliferative markers K16 and K17 showed a 
decreased expression in the Rapa-treated models. The differentiation marker K10 showed 
similar expression levels with all treatments, staining all suprabasal cell layers (data not 
shown). Taken together, these observations show that Rapa decreases the proliferation of 
keratinocytes in the skin model. All the other treatments with immunosuppressants did 
not result in signifi cantly altered epidermal regeneration, proliferation or K10, K16 and K17 
expression (data not shown), nor were there any other morphological differences. 
Cyclosporine decreases and rapamycin increases the active caspase-3 
positive cell fraction in HSE after UV irradiation
To examine the effects of immunosuppressants on a possible apoptotic response, HSEs 
from two donors were irradiated with UV (140mJ/cm2) two days after supplementation of 
immunosuppressants to the media. The percentage of active caspase-3 positive cells 24 hours 
after irradiation was determined by immunohistochemistry. Of the fi ve immunosuppressants, 
only Rapa at 10nM and 100nM increased the percentage of active caspase-3 positive (supra-)
basal cells (average 20%, SEM = 4%, vs 7%, SEM = 6%, in controls) in skin models of one 
donor with a low apoptotic response, whereas only CsA at 1μM was found to decrease the 
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apoptotic percentage (35%, SEM = 10%, vs 100%, SEM = 0%, in controls) in skin models of 





Control                                                   Rapa 100nM
Figure 1: Rapa alters epidermal regeneration, proliferation, K16 and K17 expression in HSEs. 
Representative pictures are shown. Scale bar: 100μm.
Cyclosporine and azathioprine increase numbers of mut-p53 cell clusters 
Mut-p53 cell clusters develop in chronically UV-irradiated skin, which are generally thought 
to be precursor lesions of squamous cell carcinomas that arise after continued UV exposure. 
Since HSEs are not suitable for generating mut-p53 cell clusters due to their limited lifespan, 
we examined the effects of immunosuppressants on generation of mut-p53 cell clusters in 
mice. Hairless mice were fed with immunosuppressants admixed to the chow at dosages 
resulting in blood levels that are at the high end of the range of typical blood levels in renal 
transplant recipients. Due to toxicity of Tac and Aza, dosages of these drugs were limited to 
maximal long-term tolerable levels. The mice were daily irradiated with 0.5MED UVB for 4, 
7, or 10 weeks, at which time numbers of mut-p53 positive cell clusters were determined. 
CsA and Aza treatment increased the number of mut-p53 cell clusters (p<0.001 and p<0.05, 
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respectively) (fi gure 2). Rapa tended to inhibit their formation at all time points (p=0.07). 
The proliferation index of dorsal skin from 4 week-irradiated mice was not affected by 
any of the immunosuppressants (data not shown). For comparison with p53 mutational 
frequencies (described below) we determined in 10 week-irradiated control mice the 
percentage of surface covered by the mut-p53 cell clusters in the epidermal sheet bordering 
the epidermal strip that was removed for mutational analysis; mut-p53 cell clusters covered 































Figure 2: Effects of immunosuppressive drugs on the induction of epidermal mut-p53 cell clusters 
after 4, 7 and 10 weeks of chronic UV treatment. CsA and Aza-treated mice developed increased 
numbers of mut-p53 cell clusters; Rapa-treated mice developed a lower number of mut-p53 cell 
clusters compared to control mice.
Frequency of p53 mutations in UV-exposed skin
The question arose whether the number of mut-p53 cell clusters corresponded with the 
frequency of mutated alleles in the p53 gene in the epidermis. To answer this question, DNA 
from epidermal strips of mice UV-irradiated for 10 weeks and unirradiated control mice 
was used as template to amplify part of the p53 gene containing two mutational hotspots 
(codons 270 and 275). PCR products (pooled for four mice per group) were analyzed by 
deep-sequencing, with a sequencing depth between 2 million and 8 million for the different 
samples. Three mutations were common in samples of the UV-irradiated mice: 808C>T = 
aa270 R>C, 823C>T = aa275 P>S, 824C>T = aa275 P>L, with numbers cumulating to a total 
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between 4.6% and 6.6% of the PCR products; samples from un-irradiated mice contained 
these mutations far less frequently at 0.03% (fi gure 3). There were no clear differences in 
mutational frequencies between the samples from different immunosuppressive treatments 
and controls. 
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Figure 3: Frequency of hotspot mutations in the p53 gene. DNA isolated from epidermal strips of 
mice daily UVB-irradiated for 10 weeks was analyzed by deep-sequencing the fragment-spanning 
codons 263 to 276 of the p53 gene. The three most commonly occurring mutations are presented 
in the table and in the graph as percentages of all analyzed PCR products.
Cyclosporine delays tumor induction and rapamycin inhibits tumor growth
To examine the effects of immunosuppressants on UVB-induced tumor formation, mice 
were fed immunosuppressants in the food and daily exposed to 0.5MED of UV. Tumor 
development was assessed weekly. CsA feeding resulted in increased tumor latency times 
for tumors >1mm (fi gure 4A). Confi rming earlier results (chapter 2), Rapa-fed mice showed 
no change in onset of small tumors (diameters around 1mm) but did show a lowered rate 
of formation of larger tumors, i.e. an inhibition of tumor outgrowth. Rapa and CsA groups 
showed signifi cantly lower yields of tumors >4mm compared with controls (p<0.01 and 
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p<0.001, respectively) (fi gure 4B). Near the end of the experiment, several mice had to be 
taken out of the different groups because they extensively scratched their tumors. After 155 
days, 7 of the 12 mice of the CsA group were still in the experiment compared with 9 out 
of 13 mice in the control group. None of the other immunosuppressants in the food of the 
mice appeared to affect the onset or outgrowth of the UV-induced tumors. Histopathology 
showed all tumors >4mm to be SCCs. No effect of immunosuppressive drugs on tumor type 
or grading was found.
tumors >1mm


























































































Figure 4: (A) Tumor-free surv ival (Kaplan-Meier) plots of the different treatment groups, with 
different thresholds for tumor detection: diameters >1mm or >4mm. (B) Tumor yields (average 
number of tumors per mouse) are shown for control, Rapa and CsA treatment. Error bars depict 
SEM. **p<0.01 ***p<0.001
Azathioprine did not affect UVA-induced tumor induction
Aza has been previously reported to increase the sensitivity of the skin to UVA light9. To assess 
whether Aza sensitizes mice for UVA carcinogenesis, mice were put on an Aza-containing 
diet or control diet for two weeks. No difference in minimal edemal dose was observed 
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between the two groups 24 hours after irradiation, both for albino hairless SKH1 mice, and 
for pigmented SKH1/BL6 mice. In the pigmented mice, 72 hours after irradiation, the Aza-
fed mice showed more extensive skin burning compared with control mice (supplementary 
fi gure 2). UVA carcinogenesis was therefore studied in pigmented mice. In these mice Aza 
showed no signifi cant effect on tumor yields for tumors >1mm or >2mm (supplementary 
fi gure 3). Since some mice started scratching their tumors after 19 weeks in the experiment 
they had to be removed from the experiment; as a result, tumor yield data for tumors >4mm 
could not be measured reliably.
Discussion
In this study we aimed to establish whether short-term effects of immunosuppressants on 
UV-induced apoptosis and medium term effects on p53 mutations are predictive of the risk 
of skin cancer development. Of the immunosuppressants tested in this study, Rapa showed 
an inhibitory effect on epidermal regeneration and increased UV-induced apoptosis in 
human skin models, whereas CsA decreased apoptosis. Despite corresponding effects on the 
formation of clusters of cells overexpressing mutant-p53 in mice – i.e. a decrease by Rapa, 
an increase by CsA – the effects on tumor onset were discordant. CsA was unexpectedly 
shown to delay tumor onset and Rapa had no effect on tumor onset, but inhibited 
tumor growth. Remarkably, none of the dietary fed immunosuppressants increased UV-
induced skin carcinogenesis in the mouse model employed in this study; an overview of 
the results is presented in table 1. In the following paragraphs we discuss the effects of 
immunosuppressants on UV-responses and the different stages in tumor development, viz. 
cellular responses in human skin models, mut-p53 cell clusters, p53 mutational frequencies 
and tumor development in mice.
Table 1: Summary of the results obtained for the different immunosuppressants. 
CsA Tac Aza MMF Rapa
Human skin model Epidermal regeneration − − − − ↓
Proliferation − − − − ↓
Apoptosis after UV ↓ − − − ↑
Mouse model Proliferation − − − − −
Number of mut-p53 cell clusters ↑ − ↑ − ↓
P53 mutational frequency in 
non-tumor epidermis
− − − − −
Yield of small tumors (>1mm) ↓ − − − −
Yield of large tumors (>4mm) ↓ − − − ↓
Legend: − = no effect, ↓ = inhibitory effect, ↑ = positive effect
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Rapa increased the apoptotic response of human skin models to UV exposure, whereas CsA 
inhibited this apoptotic response, which is in agreement with earlier studies in cell cultures 
and mice6, 29. Epidermal regeneration in reconstructed human skin was impaired by Rapa. 
HSEs treated with Rapa showed a thin epidermis with only a few cell layers, as well as a 
decreased proliferation index and reduced expression of the hyperproliferation markers K16 
and K17. This decreased proliferation in HSEs may be related to wound-healing problems 
associated with Rapa treatment in transplantation patients30. In HSEs, CsA pre-treatment 
caused a decrease in the apoptotic response after UV irradiation. This decrease in apoptotic 
response was only evident in HSEs with a high percentage of apoptotic cells, leaving the 
possibility that only at high UV doses CsA decreases apoptotic responses, as suggested by 
Flockhart et al.31.
CsA and Aza increased the formation of mut-p53 cell clusters in mice, whereas Rapa tended 
to inhibit mut-p53 cell cluster formation. The lower number of UV-induced mut-p53 
cell clusters formed in the skin of Rapa-treated mice is apparently not due to decreased 
proliferation, since the fraction of Ki-67 positive cells was not decreased in Rapa-treated 
mice. A previous study from our group22 showed no effect of Aza on mut-p53 cell cluster 
formation in mice, but it should be noted that Aza in these experiments was administered 
by i.p. injections, and variations in counts of these clusters were very large. 
Immunosuppressants did not affect the mutational frequency of p53 in chronically UV-
irradiated skin in mice. Deep sequencing analysis of the mutational hotspots in the p53 
gene showed that many cells harbor a mutated allele of p53. There was no clear effect of 
the immunosuppressive treatments on the frequencies of mutated p53 alleles, contrasting 
with effects on mut-p53 cell cluster formation. On average, 5% of the sequenced alleles 
were mutated, corresponding to 10% of the cells assuming heterozygous mutations. As 
the hotspot mutations at codons 270 or 275 comprise about half of the mutations in the 
p53 gene28, 32, the mutational frequency suggests that approximately 20% of the cells in 
the skin would harbor mutated p53. These results are in agreement with a recent deep 
sequencing study of human skin from middle aged individuals revealing that persistent 
p53 mutations had accumulated in 14% of the epidermal cells33. The percentage of skin 
area containing mut-p53 cell clusters was much lower, approximately 6%. It can therefore 
be concluded that a minority of the cells harboring a mutated p53 show overexpression of 
mut-p53 in cell clusters. This puts the effects of Rapa, CsA and Aza in a different perspective, 
indicating that a mutation in p53 is apparently not suffi cient to cause overexpression of the 
p53 protein in mut-p53 cell clusters34 (chapter 3), and that tumors may arise from a larger 
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pool of p53-mutated cells that do not overexpress the protein. Evidently, the local effects 
of immunosuppressants in the skin affecting the mut-p53 cell clusters are not paralleled by 
corresponding effects on p53 mutations and tumor onset.
None of the immunosuppressants increased UV-induced tumor development, and CsA 
even delayed tumor onset. Rapa had no effect on the development of small tumors, but 
decreased the outgrowth of tumors. Growth inhibition was reported earlier by our group 
(chapter 2), but the growth inhibition by Rapa was more prominent in that experiment. 
Other UV carcinogenesis studies with different treatment schemes have shown either lower 
tumor yields35 or higher tumor yields36 in Rapa-treated mice, indicating that treatment 
schemes may have important effects on the outcomes of the tumorigenesis experiments. 
Proliferation of epidermal keratinocytes was not affected by CsA, making it unlikely that 
reduced keratinocyte proliferation was causing the tumor delay. Toxicity of CsA on tumors 
is not very likely either, as a three-fold lower concentration of CsA in the diet still exerted 
the same effect (See supplementary fi gure 4). In contrast to CsA, Tac did not have any 
measured effects in this study, possibly due to the lower dose of Tac that was used to avoid 
toxicity problems. Blood levels of Tac were approximately four times lower than trough 
Tac blood levels in organ transplant recipients37. Alternatively, the effects of CsA on tumor 
development are caused by a an effect not exerted by Tac38. A pioneering study of the effect 
of CsA on UV-carcinogenesis7 showed a shorter tumor latency time compared to controls. In 
that experiment mice were administered CsA in oil by gavage three times a week, after which 
they were exposed to UV at 2 to 4 hours (corresponding to the expected peak drug levels). 
The mode of administrating CsA in our experiment results in relatively stable CsA blood 
levels over time; while using gavage results in a peak of CsA blood levels in the fi rst hours 
and decrease thereafter. With a different experimental setup, Wulff et al also showed that 
CsA treatment by repeated i.p. injections reduced the rate of development of new tumors 
in mice35. The different ways of administrating CsA result in pharmacologically different 
profi les; stable exposure to CsA when administered in the food may have different effects 
when compared to bolus injection. Further experimentation on the effect of CsA treatment 
schemes on tumor formation is called for. 
No correlation was found in this study between development of mut-p53 cell clusters 
and SCCs. Numbers of mut-p53 cell clusters had always correlated with the rate of tumor 
development in previous studies 5, 28, 39. Mut-p53 cell clusters develop as a clonal expansion 
of a mutated keratinocyte. Since most SCCs and actinic keratoses harbor mutations in the 
p53 gene, p53 mutations are considered as early events in SCC formation and therefore 
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mut-p53 cell clusters are thought to be precursors of SCCs40, 41 (fi gure 5A). However, an 
earlier retrospective study did not fi nd any differences in numbers of mut-p53 cell clusters 
between skin from patients with solitary versus multiple skin carcinomas42. As we found 
that compounds (Rapa and CsA) can have opposing effects on mut-p53 cell clusters and SCC 
formation, it follows that mut-p53 cell cluster formation cannot be used as a simple indicator 
of tumor risk. These results open up an alternative perspective on the developmental stages 
of skin carcinomas, one in which SCC development is independent of mut-p53 cell cluster 
formation (fi gure 5B).
Normal skin















Figure 5: Schematic overview of potential developmental stages in UV-carcinogenesis. (A) 
Previous model adapted from Boukamp43. (B) Model based on present results. Effects of 
immunosuppressants on different stages as described in the article are depicted.
Using the present mouse model and experimental setup, the effect of the immunosuppressive 
drugs on tumor risk appears not to be in agreement with the increased skin cancer risk in 
transplant recipients. Moreover, we did not fi nd consistent links between effects on UV-
induced apoptosis, frequency of p53 mutations and the ultimate formation of skin tumors. 
These discrepancies between the effects on mut-p53 cell clusters and tumors, and the striking 
overall lack of enhanced UV carcinogenesis in the present mouse experiments imply that 
the mouse model does not properly emulate skin cancer development in organ transplant 
recipients. Elucidation of these discrepancies, whether they are caused by the experimental 
setup or physiological differences between mice and humans, should contribute to a better 
understanding of the risk of skin carcinogenesis in organ transplant recipients. 
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Supplementary fi gure 1: Effects of immunosuppressive drugs on epidermal proliferation in HSEs 
(n=3-4) as % of Ki-67 positive (supra-)basal cells. ANOVA shows only Rapa to differ from control 
(DMSO) (p<0.05). Results for two concentrations of immunosuppressants are combined. Error 
bars depict SEM.
A A C C
Supplementary fi gure 2: Mice on Aza diet (A) show more extensive burning 72 hours after UV 
irradiation compared with mice on control diet (C). Arrows indicate area on the mice that was 
irradiated with 28 J/m2 UV.




































































































































































































































































































































































































































































Dose scheduling of cyclosporine 
determines the impact on 
UV-induced tumor development 
in mice
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Abstract
Organ transplant recipients using the immunosuppressant cyclosporine have an increased 
risk for developing nonmelanoma skin cancer. Disparate effects of cyclosporine have, how-
ever, been reported on UV-induced skin carcinogenesis in mouse experiments. Therefore, 
we set out to compare three experimental protocols using hairless mice with the aim to 
emulate most closely the increased skin cancer risk in organ transplant recipients. Using an 
experimental protocol with chronic UV exposure and continuous dietary administration 
of cyclosporine, it was shown to inhibit tumor formation. Using an experimental protocol 
in which mice were treated with dietary cyclosporine after a period of UV exposures, 
cyclosporine did not affect ensuing UV carcinogenesis. Thus, the treatment schemes where 
mice were fed cyclosporine via their chow, resulting in stable cyclosporine blood levels, 
did not show increased skin cancer development. An increase in tumor development was 
found in UV-exposed mice that were force-fed cyclosporine, resulting in strongly varying 
blood levels of cyclosporine. There was no difference in tumor development between mice 
UV irradiated during cyclosporine peak or trough blood levels. Time-averaged cyclosporine 
blood levels in these mice were similar to those with cyclosporine in the diet. The difference 
in tumor development in mice with these experimental treatments shows that cyclosporine 
in bolus doses increases skin cancer risk in contrast to even cyclosporine administration. 
Extrapolation to transplant patients suggests that the mode of administrating cyclosporine 
may be crucial for the increased skin cancer risk and that this risk might be lowered with a 
more steady release of cyclosporine in the body.
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Introduction
Organ transplant recipients (OTRs) taking immunosuppressive drugs (including cyclo-
sporine) to prevent rejection of the transplant have an increased risk for developing non-
melanoma skin cancer1-4.
The immunosuppressant cyclosporine has direct adverse effects on skin cells, which may 
contribute to carcinoma risk. It inhibits repair of UV-induced DNA damage and apoptosis of 
overly damaged cells in the skin3, 5-8. The latter is possibly due to inhibition of mitochondrial 
permeability and pore opening5, 9, 10. In immune compromised mice, cyclosporine induced 
phenotypic changes, including invasiveness of non-transformed cells, which was TGF- 
dependent11. Squamous cell carcinomas from OTRs on cyclosporine harbor less senescent 
cells than those from OTRs on other immunosuppressants12. These fi ndings indicate that 
– aside from systemic immunosuppression – local effects of cyclosporine in the skin may 
contribute to the increased skin cancer risk in transplantation patients. 
In order to systematically compare different immunosuppressive drugs on their skin cancer 
risk, several mouse studies have been performed. Mouse experiments aimed at mimicking 
the skin cancer promoting effect of cyclosporine on transplantation patients have yielded 
different outcomes. A pioneering study showed enhanced UV-induced skin carcinogenesis 
when cyclosporine was administered by gavage and UV exposure was performed twice 
weekly7. A more recent study with mice UV exposed thrice weekly showed that larger tumors 
developed with daily i.p. injections of cyclosporine13. Another study from this group showed, 
however, that UV-induced tumor development was impaired when cyclosporine treatment 
was started and UV exposure discontinued when the fi rst tumors had occurred14. A recent 
study from our group surprisingly showed that tumor formation by daily UV exposures was 
inhibited when cyclosporine was administered in the food (chapter 4). In all these studies 
the hairless SKH1 mice were used. The main differences between these studies were the 
experimental procedures regarding UV irradiation and cyclosporine administration, which 
suggests that the exact experimental protocol determines the net effect of cyclosporine on 
UV-induced skin cancer development. These different experimental outcomes led us to 
the hypothesis that UV carcinogenesis is enhanced when cyclosporine is force fed in bolus 
dosages and UV irradiation occurs during peak levels of cyclosporine in the blood.
In this study we therefore set out to compare three experimental protocols with the aim 
to em ulate most closely the increased skin cancer risk in organ transplant recipients. The 
protocols were: 
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a) cyclosporine is administered in the food of mice that are daily UV irradiated (part of our 
earlier study mentioned above, chapter 4), 
b) mice are daily UV irradiated for only fi ve weeks, and subsequently had cyclosporine 
administered in the food, and 
c) cyclosporine is administered through gavage thrice weekly each time followed by UV 
irradiation during peak or trough levels in the blood. 
Materials and methods
The mice
SKH-1 hairless mice (Charles River, Maastricht, The Netherlands) entered the experiment 
at 8-16 weeks of age; both male and female mice were used. The animals were housed 
individually under a 12 h light-12 h dark cycle at 23°C. Standard chow was supplied in ample 
amounts (60 g/mouse/week), and drinking water was available ad libitum. Cage enrichment 
was absent to prevent shielding of the animals from UV exposure. All experiments were 
performed in accordance with legislation and approval of the center’s ethics committee for 
animal experiments.
UV irradiation
Mice that received cyclosporine in the diet during the entire experiment were started on their 
diet 1 week before subjecting them to a regimen of daily UV exposure. TL-12/40W tubes 
(Philips, Eindhoven, The Netherlands; 54% output in UVB – 280 to 315nm – and 46% 
output in UVA – 315 to 400nm) were used for daily UV exposure. The lamps were mounted 
over the cages with grid covers to allow undisturbed exposure of the mice. The lamps were 
automatically switched on daily from 12.30 to 12.50 h. The threshold dose for a sunburn 
reaction (minimal edemal dose, MED) in the hairless SKH-1 mouse was ~500 J/m2 UV under 
these lamps. The lamps were dimmed both electronically and by insertion of perforated 
metal sheets to expose the mice daily to 250 J/m2 of UV radiation (0.5 MED).
Experimental protocols
A previous study by our group (chapter 4) has shown that admixing cyclosporine 150mg/kg 
to the standard mouse chow resulted in immunosuppressive average cyclosporine blood 
levels of 0.8 mg/L. No apparent differences in food intake and body weights were observed 
between the diet groups. In two of the experimental protocols cyclosporine was administered 
in the diet and in one protocol cyclosporine was administered by gavage (fi gure 1):
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Continuous protocol: Two diet groups were formed: one with cyclosporine admixed to the 
food (n=12) and a control group (n=14) without any admixture. These mice were started on 
their diets one week prior to starting daily UV exposures (0.5MED/d). Until the end of the 
experiment, the mice were daily UV-exposed and kept on their diets. This experiment was 
part of an earlier study of ours. (chapter 4).
Sequential protocol: Mice were fi rst daily exposed to UV irradiation (0.5MED/d) for a period 
of 5 weeks, and subsequently left unexposed and divided into two diet groups: one with 
cyclosporine (n=25) and a control (n=26) group without cyclosporine. 
Gavage protocol: Three groups of mice were formed. Two groups received cyclosporine 
dissolved in peanut oil by gavage three times a week. One group (n=12) was UV-exposed 
3 hours after gavage and another group (n=14) 24 hours after gavage. A control group of 
mice received peanut oil administered by gavage three times a week and was UV-exposed 3 
hours after gavage (n=14). Cyclosporine (LC labs, Woburn, MA) was dissolved in peanut oil 
(Sigma-Aldrich, St.Louis, MO) at a concentration of (1.5% w/v) and administered in 200μl 
volumes.










Figure 1: Graphical representation of the different experimental protocols that were used: 
continuous protocol, sequential protocol and gavage protocol.
Tumor assessment 
The mice were inspected weekly for tumors which were registered for each mouse individually 
on maps (thus recording location, size and form). Upon removal of animals from the 
experiment, tumors and normal skin were isolated for further analysis as described below. 
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Histology and immunohistochemistry
Biopsies were fi xed in 4% formaldehyde, dehydrated and embedded in paraffi n or snap-
frozen in liquid nitrogen. Staining for Ki-67 was performed on deparaffi nized sections (5μm) 
of mouse skin. Haematoxylin and eosin (H&E) staining was performed on deparaffi nized 
sections for tumor staging. Staging of tumors from each group was performed blinded by a 
pathologist (Dr. A. Gaumann, University of Regensburg, Germany) who is experienced in 
mouse and human pathology, including diagnosis of actinic keratoses as proper precursors 
of squamous cell carcinomas. Antigen retrieval was performed by autoclaving the sections 
in 10mM citrate buffer (pH 6.0) for 10 minutes at 110°C. Primary antibody against Ki-67 
(MIB1, Dako) was used at 1:100 dilution and goat-anti-mouse secondary antibody (E0433, 
Dako) was used at 1:200 dilution. After overnight incubation with the primary antibody at 
4°C sections were processed according to standard protocols and stained by AEC.
Epidermal thickness
Epidermal thickness was determined in H&E stained sections of dorsal skin acquired from 
mice on cyclosporine diet and daily UV exposed for 4, 7 and 10 weeks. These samples 
originated from a previous study where mice were similarly treated as in the continuous 
model in the present study regarding cyclosporine diet and UV exposures (chapter 4). 
Three photos were taken of each section with standard 40 x magnifi cation and these were 
subsequently analyzed by ImageJ software. Epidermal thickness was determined as the 
average of the number of pixels of epidermal thickness perpendicular to the surface. 
Cyclosporine bloodlevel determination
Cyclosporine blood levels and other responses to the cyclosporine diet were fi rst assessed 
in Balb/c mice. Blood samples were taken retroorbially at indicated time points during the 
day, and were subsequently analyzed by the Department of Clinical Chemistry (University 
of Regensburg) by LC-MS/MS alongside patient samples. Blood levels of hairless mice 
on cyclosporine diet were subsequently checked and found to be similar. Blood was 
taken around 11 a.m. Blood levels were also determined in hairless mice that were fed 
cyclosporine by gavage. Blood was collected by tail bleeding at different time points after 
gavage. Concentration of cyclosporine in these samples was determined by Fluorescence 
Polarisation Immuno Assay (AxSYM CYCL, Abott) by the Central Laboratory for Clinical 
Chemistry of the Leiden University Medical Center. 
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Results
Similar time-averaged blood levels of cyclosporine after gavage or 
feeding in diet
Feeding cyclosporine in the diet resulted in relatively stable cyclosporine blood levels during 
the day (0.7-1.0mg/L) (fi gure 2A). Administering cyclosporine by gavage resulted in a peak 
level after three hours (3.0mg/L), after which the level decreased and became undetectable 
(<25μg/L) after 48 hours (fi gure 2B). Averaging over time yielded mean levels of 0.8mg/L 
cyclosporine both for mice on a diet containing cyclosporine and mice fed cyclosporine by 
gavage. 































Figure 2: Cyclosporine blood levels over time for different modes of administering the drug. (A) 
cyclosporine blood levels in mice on cyclosporine-containing diet (n=3 per time point); (B) 
cyclosporine blood levels after gavage (n=4-5 per time point). Error bars depict SEM.
Decreased tumor development with cyclosporine in the diet during 
chronic UV exposure 
In the fi rst experiment (part of an earlier study, chapter 4) mice were fed cyclosporine in the 
food and daily exposed to mild UV irradiation at half of the threshold dose for a sunburn 
(0.5MED). Treatment with cyclosporine resulted in delayed tumor onset and lower yields of 
tumors >1mm and >4mm compared with controls (p<0.001) (fi gure 3A). 
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No effect on tumor development with cyclosporine diet after 
discontinuation of UV exposure
In the second experiment the cyclosporine-containing diet was started after a period of 5 
weeks of daily UV exposure (0.5MED). No skin tumors were present when the UV exposures 
were discontinued. Subsequent tumor development was assessed biweekly. Treatment with 
cyclosporine did not affect onset and yields of tumors >1mm and >4mm when compared 
with controls (fi gure 3B). 
Increased tumor formation with cyclosporine administrated by gavage
In the third experiment cyclosporine was administered by gavage three times a week. One 
group of mice receiving cyclosporine was UV exposed (1MED) three hours after gavage with 
cyclosporine blood levels at 3.0mg/L, the other group of mice receiving cyclosporine was UV 
exposed (1MED) 24 hours after gavage, with cyclosporine blood levels at 0.4mg/L (fi gure 
2B). Treatment with cyclosporine resulted in higher yields of tumors >4mm (and tended 
to be higher for tumors >1mm) compared with controls (fi gure 3C). Tumor development 
in mice irradiated 3 hours after gavage did not differ from that in mice irradiated 24 hours 
after gavage. But both of these groups differed signifi cantly from controls in yields of tumors 
>4mm (p<0.05 and p<0.001 respectively).
Tumor pathology
Tumors >4mm from the different treatment groups were examined. All tumors were classifi ed 
as invasive squamous cell carcinomas, without any discernable differences between the 
groups in tumor type and grading.
Epidermal thickness or proliferation index was not affected by 
cyclosporine
We showed that cyclosporine protects against UV-induced skin carcinogenesis when mice 
were fed cyclosporine during UV irradiations. To determine whether cyclosporine decreases 
epidermal proliferation, the epidermal thickness and Ki-67-positive cell fractions of mice UV 
irradiated for 4, 7 and 10 weeks from this earlier experiment (chapter 4) were determined. 
No effect of cyclosporine on epidermal thickness or Ki-67-positive cell fraction was found 
(fi gure 4).














































CsA Control no UV
Figure 4: Effects of cyclosporine on epidermal thickness and Ki-67 positive cell fraction. (A) 
Epidermal thickness of mice daily irradiated for 4, 7 and 10 weeks is shown. (B) Epidermal 
proliferation measured by percentage of Ki-67 positive cells after 4 weeks of UV irradiation. N=4 
in each measurement, Error bars depict SEM.
Discussion
In this study we set out to assess the effects of cyclosporine on UV carcinogenesis in mice 
using different experimental procedures. In the fi rst experiment with chronic UV-exposure 
and continuous dietary immunosuppressive treatment we surprisingly found cyclosporine 
to inhibit tumor formation. In a second experiment we simulated treatment with the 
immunosuppressant after a period of early life UV exposure and further avoidance of UV 
exposure. No effect of cyclosporine on UV-carcinogenesis was apparent in this experiment 
with mice on dietary cyclosporine after a period of 5 weeks of daily UV exposure. In the 
third experiment we assessed the effect of administering bolus dosages cyclosporine 
leading to highly variable blood levels of cyclosporine. An increase in tumor development 
occurred in UV-exposed mice that received cyclosporine by gavage. However, our hypothesis 
that UV irradiation with high cyclosporine blood levels would most strongly increase UV 
carcinogenesis was disproved. There was no difference in tumor development in mice UV-
irradiated during either peak or trough levels of cyclosporine in blood, indicating that 
cyclosporine blood level during UV exposures bore no relevance to UV carcinogenesis.
Dietary cyclosporine treatment inhibited tumor development only when it was given 
simultaneously with UV irradiation. Cyclosporine in the diet after a period of damage 
induction by UV did not affect tumor formation. Hence, the tumor inhibiting effect of 
cyclosporine in the diet was only present in the continuous model and not in the sequential 
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model. The tumor inhibiting effect of cyclosporine (possibly related to TGF-14) could not 
be explained by decreased epidermal proliferation as measured by Ki-67 positivity and 
epidermal hyperplasia. 
Cyclosporine administration by gavage resulted in increased tumor formation, confi rming 
the early experiments by Kelly et al.7. Total cyclosporine exposure in blood was similar in 
mice on a cyclosporine-containing diet and mice fed cyclosporine by gavage, as determined 
by time-averaged cyclosporine blood levels (also used as measure of cyclosporine exposure 
in cyclosporine-treated patients15). Average cyclosporine blood levels in mice were 0.8mg/L 
with the two methods of administration. In kidney transplant recipients, average cyclosporine 
blood levels of 0.28-0.45mg/L are aimed for (Therapeutic Drug Monitoring – Dutch Society of 
Hospital Pharmacists; http://www.2nvza.nl/layout/raadplegen.asp?atoom=5665). However, 
the pharmacological dynamics with the two methods of administering cyclosporine differed 
widely. Cyclosporine in the diet resulted in stable cyclosporine blood levels (0.7-1.0mg/L), 
whereas feeding cyclosporine by gavage resulted in widely varying cyclosporine blood levels 
with a peak after three hours (3.0mg/L) and undetectable levels after 48 hours. In the skin 
though, cyclosporine levels may have fl uctuated much less, as half-lives of cyclosporine in 
organs have been reported to vary between 60 and 120 hours16. Thus, the skin may become 
loaded with cyclosporine depending on its exposure to the drug. Despite similar average 
blood levels, the uptake and levels of cyclosporine in the skin may have differed importantly 
between the two methods of administering cyclosporine.
The blood level of cyclosporine at the time of UV exposure is not of importance for tumor 
formation. UV irradiation of mice 24 hours after feeding cyclosporine by gavage (trough 
blood level) or three hours after gavage (peak blood level) did not result in differences in 
tumor formation. Immunosuppression in these two groups of mice may be assumed to be 
the same and to contribute equally to the increased tumor development when compared to 
controls. However, the difference in tumor development between mice with cyclosporine 
by diet or gavage did show that evenly administered cyclosporine differed in effect from 
cyclosporine in bolus doses. An explanation for this differential effect may lie in a difference 
in immunosuppressive effect of the two methods of administering cyclosporine, or may 
be due to different cyclosporine skin levels due to the different pharmacokinetic profi les. 
Elucidation of the mechanism responsible for the differences in impact oft the modes of 
administering cyclosporine on UV carcinogenesis evidently needs further study.
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Organ transplant recipients that use cyclosporine as immunosuppressant mostly take the drug 
twice daily. This results in a pharmacokinetic profi le of cyclosporine blood levels peaking 2-3 
hours after cyclosporine intake and decreasing afterwards17. This pharmacokinetic profi le is 
similar in the mice in this study that were administrated cyclosporine per gavage. We have 
shown that cyclosporine increases skin cancer induction by UV radiation in these mice. Mice 
receiving cyclosporine in their chow, resulting in stable cyclosporine blood levels, showed 
less skin cancer induction by UV radiation. Extrapolation to transplant recipients, in which 
skin cancer risk is greatly increased, suggests that the mode of administrating cyclosporine 
might play an important role in the increased skin cancer risk. Methods resulting in more 
gradual and constant release of cyclosporine in the body may result in lower skin cancer risk. 
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Chapter 6
Summary and general discussion
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The overall aim of the study was to provide experimental data which could contribute 
toward minimizing the (skin) carcinogenic risk from immunosuppressive drugs. The 
immediate objective of the experiments described in this thesis was to determine modulating 
effects of immunosuppressants on the responses of skin cells to UV irradiation, and UV 
induction of skin carcinomas and precursor lesions. Hence, we have determined the effects 
of the immunosuppressants at several stages of tumor development. Comparison of the 
different immunosuppressants on their effects on tumor development should contribute 
to lowering skin cancer risk from immunosuppressive regimens. Unexpectedly, none of 
the immunosuppressants fed in long-term tolerable dosages (assessed by blood cell counts 
and/or condition of the animals) enhanced UV carcinogenesis (chapters 2 and 4). CsA 
even delayed UV carcinogenesis (chapter 4). Evidently, these mouse experiments did not 
simulate the enhanced risk of skin carcinogenesis in human organ transplant recipients. 
Our experiments suggest that immunosuppressants do not necessarily accelerate UV 
carcinogenesis. Feeding CsA in bolus dosages (by gavage) instead of evenly in the diet 
reproduced the speeding up of UV carcinogenesis as found by Kelly et al.1 (chapter 5). Thus, 
our experiments demonstrated the potential importance of the dose schedule and ensuing 
profi les in blood levels of the immunosuppressive drug. However, even in bolus dosages of 
CsA the impact on experimental UV carcinogenesis did not appear to match the dramatic 
increase in risk of skin carcinoma in human organ transplant recipients (60- to 100-fold 
increase2). This suggests that the mouse model we used was not quite adequate, either 
because mice react differently (e.g. lower rate of DNA repair) or the model is incomplete, 
e.g. most prominently by the absence of an actual graft (absence of continuous antigenic 
stimuli and possible tolerance).
Interestingly, the close correspondence between the induction of mut-p53 cell clusters 
and skin carcinomas reported earlier by our group3, 4 was not observed when feeding 
immunosuppressants like CsA and Rapa (chapters 3 and 4). These results indicate that 
the large majority of mut-p53 cell clusters are probably not potential precursors of skin 
carcinomas, in contrast with earlier conclusions3, 5. Consequently, the frequency of mut-p53 
cell clusters in the skin is not a reliable predictor of skin carcinoma risk, again invalidating 
earlier inferences3, 4.
Thus, our study has yielded four unanticipated major fi ndings:
a) Immunosuppressants per se do not necessarily enhance UV carcinogenesis and in this 
respect dose scheduling can be of major importance.
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b) The mouse model with administration of immunosuppressants appears inadequate 
in simulating the increase in risk of squamous cell carcinomas in human organ 
transplant recipients.
c) Mut-p53 cell clusters in majority are not potential precursors of squamous cell 
carcinomas.
d) Early local carcinogenic effects from various immunosuppressants as expressed by 
p53 mutation frequencies in the UV-exposed mouse skin (or rather the lack of such 
effects) are not predictive of the overall effects on UV carcinogenesis. This latter 
fi nding indicates that systemic and not local effects are of major importance for the 
effects of immunosuppressants on UV carcinogenesis.
In the following paragraphs the effects of immunosuppressive drugs on UV-response 
in normal skin, p53 mutations, mutant-p53 overexpressing cells and skin tumors are 
discussed in more detail. Consequences of these effects for the model of UV-induced tumor 
development are discussed, followed by concluding remarks and future directions. 
Effects of immunosuppressants on epidermal regeneration and responses 
to UV in human skin equivalents
Some immunosuppressants have direct adverse effects on skin cells, which could contri-
bute to carcinoma risk. CsA affects DNA repair6, 7 and has been shown to impair apoptotic 
responses induced by UV in normal human keratinocytes6 and mice8. Aza enhances 
DNA damage by photosensitization9. In chapter 3 and 4 we systematically compared 
the impacts of the immunosuppressants on epidermis and responses to UV exposure in 
human skin equivalents (HSEs). Epidermal regeneration (formation of an epidermis 
by seeded keratinocytes) in HSEs was impaired by Rapa. HSEs treated with Rapa show a 
thin epidermis with only a few cell layers, as well as a decreased proliferation index and 
reduced expression of the hyperproliferation associated markers K16 and K17. Decreased 
proliferation may be relevant to wound-healing problems associated with Rapa treatment 
in transplantation patients10. None of the other immunosuppressants showed any effect on 
epidermal regeneration. 
The apoptotic response after UV exposure in HSEs was increased after Rapa treatment. In 
our mouse experiments (chapter 3) we did, however, not see any signifi cant increases in 
apoptosis in Rapa-treated mice which could be attributable to a wide variation in responses. 
In HSEs CsA pre-treatment caused a decrease in the apoptotic response after UV irradiation, 
confi rming earlier results in cell cultures6. 
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We found HIF1 accumulation to be inhibited by Rapa in keratinocytes after UV exposure 
of HSEs, while the apoptotic response was increased by Rapa. Previously it has been shown 
that HIF1 is upregulated after hypoxia11 and UV irradiation12, 13 and that Rapa can prevent 
hypoxia-induced HIF1 accumulation14. Here we have shown that Rapa is also able to 
inhibit UV-induced HIF1 accumulation (chapter 3). HIF1 is known to inhibit or induce 
apoptosis depending on the cell type, and inhibition of HIF1 accumulation may therefore 
be involved in the pro-apoptotic effect of Rapa in HSEs15, 16. 
Immunosuppressants and UV-induced p53 mutations
In chronically UV-irradiated skin, clusters of cells expressing mutated p53 (mut-p53 cell 
clusters) develop. These cell clusters harbor similar mutations in the p53 gene as the skin 
tumors that arise later17. Also the development of these cell clusters correlated with skin 
tumor development in several studies3, 4, therefore these cell clusters are generally regarded 
as precursor lesions for squamous cell carcinomas that arise after continued UV exposure3, 
17-19. Immunosuppressants do not affect the mutational frequency of p53 in chronically UV 
irradiated non-tumor skin in mice (chapter 4). Deep sequencing of two mutational hotspots 
in the p53 gene (codons 270 and 275) showed that many cells harbor a mutated allele of 
p53. There was no clear effect of the immunosuppressive treatments on the frequencies of 
mutated p53 alleles. On average, 5% of the alleles sequenced were mutated in a stretch of 40 
bp, corresponding to 10% of the cells when assuming heterozygously mutated cells (total 
mutations in p53 were therefore estimated to amount 20%). These results are in agreement 
with a recent deep sequencing study of human skin from mid-life individuals that revealed 
that persistent p53 mutations had accumulated in 14% of the epidermal cells20. In contrast 
to the mutational frequencies, immunosuppressants did affect formation of mut-p53 cell 
clusters. CsA and Aza increased the formation of mut-p53 cell clusters in mice, whereas 
Rapa inhibited mut-p53 cell cluster formation (chapters 3 and 4). The lower number of 
UV-induced mut-p53 cell clusters formed in the skin of Rapa-treated mice might be caused 
by early enhanced apoptosis or decreased proliferation, but Ki-67-positive cells were not 
decreased in Rapa-treated mice. A previous study by our group showed no effect of Aza 
on mut-p53 cell cluster formation in mice21, but Aza was administered by i.p. injections 
in those experiments, and the measurement was limited to one time point with relatively 
large error margins in the counts. The discrepancy between p53 mutational frequencies and 
mut-p53 cell cluster formation is discussed below.
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Immunosuppressants and UV-induced tumor development in mice
Effects of immunosuppressants on UV-induced skin cancer were determined in daily UV-
irradiated mice fed with drug-containing chow (chapters 2 and 4). Surprisingly, none of 
the immunosuppressants increased UV-induced tumor development. Remarkably, tumor 
induction was delayed by CsA treatment. Proliferation of epidermal keratinocytes (e.g. 
through TGF-) was not affected by CsA, making it unlikely that reduced keratinocyte 
proliferation caused the tumor delay. A pioneering study on the effect of CsA on UV 
carcinogenesis showed a shorter tumor latency time compared to controls1. With a different 
experimental setup, Wulff et al. showed that CsA treatment (by repeated i.p. injections) 
reduced the rate of new tumor development in mice22, in agreement with our results. 
We found that Rapa had no effect on the development of small tumors, but impaired 
the development of large tumors (chapter 2). This impairment can be attributed to the 
known anti-tumor, or more specifi cally, antiangiogenic effects of Rapa23, 24. At dosages 
that maintained allogeneic heart grafts in mice, Rapa was described to inhibit outgrowth 
of tumor implants whereas CsA enhanced angiogenesis and strongly stimulated tumor 
outgrowth25. Rapa could even block the proangiogenic effect from CsA. In chapter 2 the 
inhibition of tumor outgrowth by Rapa appeared to be refl ected by a signifi cant reduction of 
Vegf-a positive tumor cells. Interestingly, we did not fi nd any clear effect on the vasculature 
of tumors that grew in the Rapa-fed groups, but these tumors may be presumed to have been 
selected for their vascularization and resistance to Rapa whereas those that lagged behind 
were most sensitive to the antiangiogenic effect of Rapa. Other UV carcinogenesis studies 
with different treatment schemes have shown either lower tumor yields22 or higher tumor 
yields26 in Rapa-treated mice, indicating that treatment schemes can have important effects 
on the outcomes of the tumorigenesis experiments.
P53 mutational spectra in SCCs 
P53 mutations appear to be involved in the early stages of tumor development3. Our 
hypothesis that Rapa might selectively induce apoptosis in the p53-mutated cells, and thus 
slow down the rate at which tumors are initiated, was not supported by our data because 
we found no effect on the onset of the smallest perceptible tumors (<1mm) (chapter 2). To 
check further for local effects of the immunosuppressants on the epidermal cells that might 
have affected UV carcinogenesis (e.g., disturbed metabolism by Rapa), we investigated the 
p53 mutation spectrum of the tumors, which is normally dominated by the UV signature 
mutations (i.e. C>T transition on a dipyrimidine site)27. We found a dramatic shift in the 
types of mutations in tumors from the Rapa-fed group. Since Rapa-insensitivity can be 
acquired via increased cellular oxidative stress28 it is possible that only tumors with high 
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levels of endogenous oxidative stress could grow into large tumors, hence causing the altered 
mutational spectrum. The antioxidant effect of MMF29 may have prevented formation of 
non-UV-type mutations in tumors of mice on a combination diet with Rapa and MMF, 
although tumor development was not different in mice on combined MMF and Rapa diet 
than on Rapa diet. We further determined in chapter 3 that this shift in the type of mutations 
occurs only in tumors >2mm and not in mut-p53 cell clusters or skin tumors <2mm in mice 
treated with Rapa. It can therefore be concluded that the altered mutational spectrum is a 
late event in tumor development. Either it occurred after the initial development of small 
tumors, or a specifi c selection of small tumors with altered mutational spectra grew into 
large tumors, corresponding to the lower yield of large tumors in Rapa-fed mice. 
Discrepancies between effects of immunosuppressants at different 
stages of tumor development in mice
There was no clear effect of the immunosuppressive treatments on the frequencies of mutated 
p53 alleles, in contrast with effects on mut-p53 cell cluster formation. Deep sequencing 
of the mutational hotspot in the p53 gene (codons 270 and 275) showed that many cells 
(~20%) harbor a mutated allele of p53 before the occurrence of tumors. The percentage of 
skin area containing mut-p53 cell clusters was much lower, approximately 6% in control 
mice. It can therefore be concluded that a minority of the cells harboring a mutated p53 
show overexpression of mut-p53 in cell clusters. This puts the effects of Rapa, CsA and Aza in 
a different perspective. A mutation in p53 is apparently not suffi cient to cause overexpression 
of the p53 protein in mut-p53 cell clusters30, in agreement with what we found in mut-p53 
mice (chapter 3). Tumors may arise from a larger pool of p53-mutated cells that do not 
overexpress the protein. Development of mut-p53 cell clusters and SCCs was not strictly 
correlated in our experiments. When mice were treated with CsA, numbers of mut-p53 cell 
clusters were clearly increased compared to controls, but CsA delayed tumor onset. Rapa 
on the other hand reduced mut-p53 cell clusters without any effect on the onset of small 
tumors. Numbers of mut-p53 cell clusters had in previous studies always shown a good 
correlation with the rate of tumor development with chronic UV irradiation3, 4, 31. Since 
most SCCs harbor mutations in the p53 gene, p53 mutations were considered early events in 
SCC formation and therefore mut-p53 cell clusters were thought to be precursors of SCCs 
(Chapter 4 fi gure 5A)18, 32. However, a retrospective study did not establish differences in 
numbers of mut-p53 cell clusters between skin from patients with solitary versus multiple 
skin carcinomas33. As we found that immunosuppressants can have opposing effects on 
mut-p53 cell clusters and SCC formation, this suggests that mut-p53 cell cluster formation 
cannot be used as a simple indicator of tumor risk. As most mut-p53 cell clusters are 
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not genuine precursors of SCC, another oncogenic early event is likely to drive early UV 
carcinogenesis. The necessity of another oncogenic event might also explain the absence 
of an increased SCC risk among Li-Fraumeni patients, i.e. people heterozygous in germline 
mutations in p53. These results open up an alternative perspective on the developmental 
stages of skin carcinomas, in which mut-p53 cell clusters do not contribute to skin carcinoma 
risk (Chapter 4 fi gure 5B).
Dose schedule of CsA determines effect on experimental UV 
carcinogenesis
In order to systematically compare different immunosuppressive drugs on their skin cancer 
risk, several mouse studies have previously been performed. Mouse experiments aimed at 
mimicking the skin cancer promoting effect of CsA on transplantation patients have resulted 
in different outcomes. A pioneering study showed enhanced UV-induced skin carcinogenesis 
with CsA when the drug was administered through force feeding and UV exposure was 
performed twice weekly1. A more recent study showed that CsA administration resulted in 
larger UV-induced skin tumors compared to control when CsA was administered via i.p. 
injections daily and UV exposures thrice weekly26. Another study from this group showed 
that CsA decreased UV-induced tumor development when CsA treatment is started and UV 
treatment was discontinued when the fi rst tumors had occurred22. In chapter 4 we showed 
that CsA inhibited UV-induced tumor formation when CsA was administered in the food 
and with daily UV exposures. In all these studies the hairless SKH1 mice were used. The main 
differences between these studies were the experimental procedures regarding UV irradiation 
and CsA administration, which suggests that the exact experimental protocol determines the 
effect of CsA on UV-induced skin cancer development. These differential outcomes led us to 
the hypothesis that when mice are force-fed CsA and repeatedly UV irradiated at times when 
they have high CsA blood levels that this would increase UV carcinogenesis. In chapter 5 we 
set out to assess the effects of CsA on UV carcinogenesis in mice using different experimental 
procedures. No effect of CsA on UV carcinogenesis was apparent in mice treated with dietary 
CsA after a period of UV exposures. An increase in tumor development occurred in UV-
exposed mice that were CsA treated by gavage. This confi rmed the results of the earlier 
experiments by Kelly et al.1. However, there was no difference in tumor development in 
mice UV irradiated during CsA peak blood levels or trough blood levels, indicating that 
CsA blood level during UV exposures bore no relevance to the increased UV carcinogenesis. 
Evidently, a more evenly administered CsA lowers (the risk of) UV carcinogenesis. 
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Concluding remarks and future perspectives
The studies described in this thesis confi rm the potential that Rapa, or Rapa analogs like 
everolimus, may have for decreasing skin cancer in organ transplant recipients. Inhibition 
of tumor growth by Rapa should be further exploited in immunosuppressive treatment of 
organ transplant recipients, and by generating proper analogs this benefi cial effect might be 
retained while eliminating adverse side effects. 
We have shown that most mut-p53 cell clusters are not genuine precursors of SCCs. It 
remains likely that SCCs develop from mut-p53 cell clusters, since mutation of the p53 
gene is an early event in tumor development34. The effects of immunosuppressants on the 
development of mut-p53 cell clusters without correspondingly altering tumor onset make 
it possible to use these drugs in identifying a novel oncogenic event that drives early UV 
carcinogenesis.
The studies described here have shown that the mouse models of UV carcinogenesis with 
immunosuppressants may be basically unsuitable to emulate the increased risk of cutaneous 
SCC in organ transplant recipients. But it is also possible that the models lack an essential 
component like the graft. Considering the strong immunogenic and tolerogenic effects from 
a graft and likely interference thereof with skin tumor immunity, it would appear probable 
that inclusion of a graft in the model will have a great impact. 
Table 1: Effects of immunosuppressants on cellular processes in non-immunological cells, based 
on majority view of literature. 
CsA Tac Aza MMF Rapa
Proliferation ↓ 35-37 ↓ 37, 38 ↓ 39-42 ↓ 43, 44
Photogenotoxicity ↑ 9
DNA repair ↓ 6, 7, 45-47 ↓ 6, 47
Apoptosis ↓ 6, 8 ↓ 6 ↑/↓ 48-52
Angiogenesis ↑ 24, 25 ↓ 53, 54 ↓ 39, 55, 56 ↓ 24, 25, 53
Legend: ↓ = inhibitory effect, ↑ = positive effect
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Orgaantransplantatie en huidkanker
Sinds de jaren zestig zijn orgaantransplantaties tussen mensen steeds vaker succesvol. 
Een belangrijke rol daarin hebben medicijnen die het afweersysteem onderdrukken 
(immuunsuppressiva) en daarmee afstoting van het getransplanteerde orgaan voor-
komen. Naarmate de levensduur van patiënten met een donororgaan toenam bleek ook 
het risico op kanker bij deze patiënten dramatisch toe te nemen. Vooral het risico op het 
plaveiselcelcarcinoom van de huid is sterk verhoogd in deze patiëntengroep vergeleken met 
de algemene populatie. Risico op huidkanker is duidelijk gerelateerd aan ultraviolet (UV) 
licht blootstelling. Dat geldt ook voor transplantatiepatiënten, waarbij de huidkankers met 
name op zonbeschenen lichaamsdelen ontstaan. In Europa en de VS hebben 40-61% van 
de orgaantransplantatiepatiënten huidkanker ontwikkeld binnen 20 jaar, in het zonnige 
Australië ligt dat percentage zelfs op 70-82%. 
Immuunsuppressiva
De immuunsuppressiva waarmee transplantatiepatiënten behandeld worden, kunnen 
ingedeeld worden in drie categorieën: remmers van calcineurine (cyclosporine en 
tacrolimus), purine synthese (azathioprine en mycofenolaat mofetil (MMF)) of mTOR 
(rapamycine). Deze immuunsuppressiva remmen de activatie en deling van T-cellen. De 
immuunsuppressieve therapie voor orgaantransplantatiepatiënten was aanvankelijk gericht 
op een optimale onderdrukking van immuunreacties tegen het donororgaan, waarbij het 
toegenomen risico op kanker als min of meer onvermijdelijk werd geaccepteerd. Door 
onderzoek is echter ook bekend geworden dat een aantal van deze medicijnen niet uitsluitend 
op cellen van het immuunsysteem effect heeft. Cyclosporine remt herstel van beschadigd 
DNA en kan evenals azathioprine geprogrammeerde celdood verhinderen (belangrijke 
processen om het lichaam te beschermen tegen gemuteerde cellen). In tegenstelling 
hierop hebben de nieuwere immuunsuppressiva MMF en rapamycine juist een remmende 
werking op tumorontwikkeling. Dit geeft aan dat het risico op huidkanker bij personen 
met orgaantransplantaties mogelijk sterk verminderd kan worden door aanpassing van de 
immuunsuppressieve behandeling. Om ethische en praktische redenen kunnen de effecten 
van verschillende immuunsuppressiva op processen betrokken bij kankerontwikkeling niet 
experimenteel onderzocht worden bij patiënten. Bij de experimenten beschreven in dit 
proefschrift is daarom voornamelijk gebruik gemaakt van twee modellen: een huidmodel 
en een muismodel. 
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Doel van de studies
Het centrale doel van de studies beschreven in dit proefschrift was om experimentele gegevens 
te verkrijgen die bij kunnen dragen aan het verminderen van het huidkankerrisico dat wordt 
veroorzaakt door immuunsuppressieve therapie. Dit is verder toegespitst op het bepalen 
van effecten van immuunsuppressiva op de reactie van huidcellen op UV blootstelling en 
effecten op UV-geïnduceerde huidkankerontwikkeling. We hebben hiervoor effecten van 
immuunsuppressiva op verschillende stadia van huidkankerontwikkeling in kaart gebracht. 
Het op deze wijze vergelijken van effecten van immuunsuppressiva kan bijdragen aan de 
vermindering van het risico op huidkanker. 
Humaan huidmodel
Het humane huidmodel dat is gebruikt bestaat uit een dermale collageenmatrix waarin 
fi broblasten zijn gezaaid met daarboven een epidermis bestaande uit keratinocyten. Dit 
huidmodel bestaat uit primaire humane cellen en is goed vergelijkbaar met de humane 
huid wat betreft morfologie en expressie van diverse karakteristieke eiwitten. Dit model is 
daarom geschikt om de reactie van keratinocyten op UV blootstelling te bepalen. De meeste 
huidmodellen kunnen slechts een beperkte tijd in kweek worden gehouden en zijn daarom 
niet geschikt voor het bepalen van lange termijn effecten van herhaalde UV blootstelling.
Haarloze muis
De haarloze muis (SKH1) is een veelgebruikt model bij studies naar huidkankerontwik-
keling door UV. Deze muizen hebben een functionerend immuunsysteem en de huid lijkt 
in veel opzichten op die van de mens. Wanneer haarloze muizen herhaaldelijk blootgesteld 
worden aan UV ontwikkelen zich in de epidermis clusters van cellen die gemuteerd p53 tot 
expressie brengen (mutant-p53 celclusters). Deze mutant-p53 celclusters ontstaan als een 
clonale expansie van een gemuteerde keratinocyt en zijn al aanwezig voordat huidkankers 
zich ontwikkelen. De huidtumoren die ontstaan zijn voornamelijk plaveiselcelcarcinomen 
en goedaardige voorlopers daarvan (actinische keratosen). Aangezien de meeste 
plaveiselcelcarcinomen een gemuteerd p53 bevatten met vergelijkbare mutaties als in 
mutant-p53 celclusters, wordt het muteren van p53 als een vroege gebeurtenis beschouwd in 
tumorvorming en worden mutant-p53 celclusters als voorlopers van plaveiselcelcarcinomen 
gezien. Zoals eerder genoemd zijn plaveiselcelcarcinomen het type kanker waarvan de 
incidentie het meest verhoogd is in orgaantransplantatiepatiënten. Haarloze muizen lijken 
daarom geschikt om effecten van immuunsuppressiva op UV-geïnduceerde huidkanker te 
onderzoeken. 
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Effecten van immuunsuppressiva op huidmodellen
In hoofdstukken 3 en 4 zijn de effecten van immuunsuppressiva op de epidermis en reactie 
van de huid op UV-blootstelling onderzocht in humane huidmodellen. De opbouw van 
de epidermis werd geremd door rapamycine, zichtbaar door onder andere een verminderd 
aantal levende cellagen en een verminderd percentage delende cellen. Het aantal cellen 
dat apoptotisch werd (geprogrammeerde celdood ondergaand) na UV blootstelling was 
verhoogd in huidmodellen met rapamycine. De apoptotische reactie na UV blootstelling 
werd juist geremd door cyclosporine, in overeenstemming met eerdere bevindingen. Het 
eiwit HIF1, dat een belangrijke rol speelt in het reguleren van metabole processen in een 
cel, accumuleerde in keratinocyten in UV bestraalde huidmodellen. Rapamycine remde 
deze accumulatie van HIF1 (hoofdstuk 3). HIF1 kan apoptotische reacties van cellen 
beïnvloeden en kan daarom betrokken zijn bij het pro-apoptotische effect van rapamycine 
in huidmodellen. In tegenstelling tot cyclosporine kan rapamycine dus de vorming van 
kwaadaardige cellen ondervloed van UV tegengaan door de groei te remmen en door de 
sterfte onder beschadigde cellen op te voeren.
Immuunsuppressiva en UV-geïnduceerde p53 mutaties en mutant-p53 
celclusters
P53 mutaties zijn vroege gebeurtenissen in het ontstaan van huidkanker. Om effecten 
van immuunsuppressiva op het ontstaan van deze mutaties te onderzoeken hebben we 
mutatiefrequenties in p53 bepaald in muizenhuid die gedurende 10 weken was blootgesteld 
aan UV, nog voordat tumoren ontstonden (hoofdstuk 4). Door middel van deep-sequencing 
(hiermee wordt de sequentie van miljoenen DNA moleculen tegelijk bepaald) is bepaald dat 
veel cellen een gemuteerd allel van p53 bevatten (naar schatting 20%). Er was geen effect van 
immuunsuppressiva op de mutatiefrequenties.
In tegenstelling tot deze mutatiefrequenties hadden immuunsuppressiva wel effect op de 
ontwikkeling van mutant-p53 celclusters. Cyclosporine en azathioprine versnelden de 
ontwikkeling hiervan in muizen, terwijl rapamycine deze juist vertraagde (hoofdstukken 
3 en 4). De discrepantie tussen de effecten van immuunsuppressiva op p53 mutatie-
frequenties in de huid en de ontwikkeling van mutant-p53 celclusters wordt verderop in dit 
hoofdstuk behandeld.
Immuunsuppressiva versnelden huidkankerontwikkeling niet
Effecten van immuunsuppressiva op UV-geïnduceerde huidkanker zijn bepaald in muizen 
die dagelijks zijn blootgesteld aan UV en die immuunsuppressiva via het voer kregen 
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toegediend (hoofdstukken 2 en 4). Onverwacht bleek dat geen van de immuunsuppres-
siva de huidkankerontwikkeling versnelde. Muizen op cyclosporinedieet vertoonden zelfs 
een vertraagde huidkankerontwikkeling. Epidermale proliferatie was niet verminderd door 
cyclosporine, waardoor het onwaarschijnlijk is dat dit de oorzaak was van de vertraagde 
tumorontwikkeling. Eerdere studies hebben verschillende effecten van cyclosporine 
op huidkanker laten zien, zowel vertragend als versnellend. Rapamycine had geen effect 
op het ontstaan van de eerste kleine tumoren maar remde de ontwikkeling van grote 
tumoren (hoofdstuk 2). Dit kan veroorzaakt zijn door de bekende tumorgroei remmende 
eigenschappen (remming van bloedvatvorming) van rapamycine. 
Rapamycine verandert het p53 mutatiespectrum in huidkankers
Het vermoeden dat rapamycine selectief apoptose induceert in p53-gemuteerde cellen en 
daarom tumorontwikkeling remt lijkt onwaarschijnlijk, omdat rapamycine het ontstaan 
van kleine tumoren (<1mm) niet remt (hoofdstuk 2). Om andere lokale effecten van 
immuunsuppressiva te onderzoeken is het spectrum van mutaties in het p53 gen bepaald 
van tumoren. Normaliter is de meerderheid van deze mutaties van het UV-type (C>T transitie 
op een dipyrimidineplaats), maar in de tumoren van muizen op rapamycinedieet was dit 
sterk veranderd. Een grote verschuiving in het type mutaties was opgetreden waardoor de 
meerderheid van de mutaties niet van het UV-type waren. Deze verandering in mutaties 
kan het gevolg zijn van een verhoogd niveau reactief zuurstof. In tumoren van muizen op 
een combinatiedieet van rapamycine en MMF was het mutatiespectrum echter onveranderd 
ten opzichte van controles, wat veroorzaakt kan zijn door het antioxidante effect van MMF. 
In hoofdstuk 3 hebben we laten zien dat dit veranderde mutatiespectrum niet optrad in 
kleine tumoren en mutant-p53 celclusters van muizen op rapamycinedieet. Het veranderde 
mutatiespectrum is daarom een late gebeurtenis in tumorontwikkeling die pas optreedt na 
de ontwikkeling van kleine tumoren, of veroorzaakt wordt door een selectiemechanisme 
waardoor alleen een specifi eke selectie van kleine tumoren kon uitgroeien. Aangezien 
ongevoeligheid voor rapamycine kan worden verkregen door verhoogde oxidatieve stress is 
het denkbaar dat alleen tumoren met verhoogde oxidatieve stress snel door kunnen groeien, 
waarbij ook het veranderde mutatiespectrum in grote tumoren is ontstaan.
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De meeste mutant-p53 celclusters hebben niet de potentie om zich tot 
huidkanker te ontwikkelen
In hoofdstukken 2, 3 en 4 worden de effecten van immuunsuppressiva op verschillende 
stadia in huidkankerontwikkeling beschreven. Er zijn discrepanties tussen effecten van 
immuunsuppressiva in de verschillende stadia:
 − Geen van de immuunsuppressiva had effect op het percentage cellen met gemuteerd p53 
in dagelijks UV-bestraalde huid (tumorvrije huid). 
 − De ontwikkeling van mutant-p53 celclusters werd verlaagd door rapamycine en verhoogd 
door cyclosporine.
 − Tumorontwikkeling werd door cyclosporine vertraagd.
 − Tumorgroei werd door rapamycine vertraagd.
Met name de effecten op ontwikkeling van mutant-p53 celclusters zijn anders dan verwacht 
kan worden op basis van het bestaande algemene model voor huidkankerontwikkeling 
door UV. Daarbij worden mutant-p53 celclusters als directe voorlopers van huidtumoren 
beschouwd met gelijke ontwikkelingsdynamiek. Dit is vooral duidelijk bij cyclosporine, 
waarbij geen effect op het percentage p53 gemuteerde cellen optreedt, de ontwikkeling van 
mut-53 celclusters wel verhoogd is, maar tumorontwikkeling vertraagd is. Ook de resultaten 
voor rapamycine laten zo’n discrepantie zien voor mutant-p53 celclusters. Aan de hand van 
deze resultaten concluderen we dat ontwikkeling van mutant-p53 celclusters niet direct 
samenhangt met huidkankerontwikkeling, maar dat deze celclusters naast en onafhankelijk 
van huidtumoren ontstaan uit een grote poule van mutant-p53 cellen. 
Experimenteel protocol is bepalend voor het effect van cyclosporine op 
huidkankerontwikkeling door UV
In het verleden zijn verschillende muizenstudies gedaan om de effecten van immuun-
suppressiva op huidkankerontwikkeling te onderzoeken. Studies die onderzoek naar het 
effect van cyclosporine op huidkanker beschrijven hebben verschillende uitkomsten. Eén van 
de eerste studies laat zien dat huidkankerontwikkeling verhoogd wordt door cyclosporine en 
een recente studie beschrijft dat cyclosporine ook de groei van tumoren verhoogt. Een andere 
studie laat daarentegen zien dat cyclosporine tumorontwikkeling remt, in overeenstemming 
met hoofdstuk 4 van dit proefschrift. Al deze studies maken gebruik van dezelfde stam haarloze 
muizen en huidkankerinductie door UV, ze verschillen echter in het protocol waarmee de 
cyclosporine wordt toegediend en in welke periode de muizen worden blootgesteld aan 
UV. Hoofdstuk 5 beschrijft de verschillen tussen drie verschillende protocollen in de 
effecten van cyclosporine op huidkankerontwikkeling door UV. Cyclosporine had geen 
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effect op huidkankerontwikkeling in muizen die op cyclosporinedieet werden gezet na een 
periode van UV blootstelling. Daarentegen vond verhoogde tumorontwikkeling plaats in 
muizen die cyclosporine toegediend kregen door middel van gavage ( sondevoeding). Dit 
bevestigde dat cyclosporine de huidkankerontwikkeling door UV kan bevorderen. Er was 
geen verschil in huidkankerontwikkeling tussen muizen die UV-bestraald werden na gavage 
op het moment dat cyclosporine bloedniveaus piekten of op het moment dat ze laag waren. 
Deze experimenten geven aan dat bloedniveaus van cyclosporine op het moment van UV 
blootstelling niet van belang zijn op het huidkankerbevorderende effect. Het toedienen van 
cyclosporine in bolus doseringen (via gavage) in plaats van een gelijkmatige toediening via 
het voer resulteerde in een versnelde huidkankerontwikkeling. Hieruit blijkt dat de manier 
van toediening van immuunsuppressiva belangrijk kan zijn voor effecten op de ontwikkeling 
van huidkanker. Maar zelfs de toediening van cyclosporine in bolus doseringen resulteerde 
niet in een verhoogde huidkankerontwikkeling in de mate die bij transplantatiepatiënten 
wordt gezien (60- tot 100-voudige toename). Dit suggereert dat het muismodel dat gebruikt 
is niet optimaal was, omdat muizen anders reageren dan mensen (bijvoorbeeld langzamer 
herstel van beschadigd DNA) of omdat het model niet compleet is door bijvoorbeeld het 
ontbreken van een orgaantransplantaat. 
Ontwikkelingen
De studies in dit proefschrift bevestigen het potentieel dat rapamycine (of analogen 
zoals everolimus) heeft om het verhoogde huidkankerrisico bij transplantatiepatiënten 
te verminderen. Remming van tumorgroei door rapamycine-analogen met minder bij-
werkingen dient verder onderzocht en ontwikkeld te worden. Dit zou voor de patiënt een 
verbetering op kunnen leveren. 
De meerderheid van de mutant-p53 celclusters zijn geen voorlopers van plaveisel-
celcarcinomen. Toch is het waarschijnlijk dat de meeste plaveiselcelcarcinomen ontstaan 
uit cellen met gemuteerd p53 aangezien mutatie van p53 een vroege gebeurtenis is in de 
ontwikkeling van deze tumoren. Een nog onbekende oncogene gebeurtenis zou echter 
vooraf kunnen gaan aan de p53 mutatie.
De hier beschreven studies laten zien dat de gebruikte muismodellen voor huidkanker-
ontwikkeling door UV niet het door immuunsuppressiva verhoogde huidkankerrisico 
in transplantatiepatiënten nabootsen. Het is mogelijk dat het muismodel een belangrijk 
element mist, namelijk het transplantaat, en daarmee ook de mogelijke tolerantie hiervoor. 
Als belangrijk en logisch vervolg op het hier beschreven onderzoek zou dus een transplantaat 
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en de daarbij behorende tolerantie in het UV carcinogenese model met de haarloze muis 
moeten worden opgenomen. 
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CPD Cyclobutane pyrimidine dimer
HIF1 Hypoxia-inducible factor 1, alpha subunit
HSE Human skin equivalent
MED Minimal erythemal/edemal dose
MMF Mycophenolate mofetil
MPA Mycophenolic acid
mTOR Mammalian target of rapamycin
NFAT Nuclear factor of activated T-cells
NMSC Non-melanoma skin cancer
OTR Organ transplant recipient





VEGF Vascular endothelial growth factor
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